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Executive Summary 
Introduction 
Health Problem 
This systematic review is focused on patients with irreparable rotator cuff 
tears. The rotator cuff is comprised of several muscles, with tendons that 
stabilize the shoulder. When one or more of the rotator cuff tendons are torn, 
either following trauma or normal wear and tear, the patient experiences pain 
and restricted movement of the arm. Rotator cuff tear can usually be repaired 
with surgery. An irreparable rotator cuff tear is defined as large (>3 cm) or 
massive (>5 cm), involving two or more tendons, or one which has under-
gone primary surgery without success. 
Around 30.0% of patients presenting with rotator cuff tears may have mas-
sive irreparable tears and post-operative re-tear rates after primary surgical 
repair of rotator cuff tears range from 20.0 to 90.0%. 
Description of Technology 
Human dermal allograft is a type of augmentation graft which can be incor-
porated into the musculotendinous bone complex in tendon repair to improve 
the likelihood of fixation. While grafts are usually derived from animal tissue 
(xenograft) or artificially manufactured with synthetic materials, this type 
uses tissue from other humans – in this case cadaveric donors. 
Human dermal allograft is used in the superior capsular reconstruction tech-
nique to improve graft consistency and reduce the likelihood of complications 
or failure of the procedure. The technology is intended for patients with ir-
reparable rotator cuff tears, where there is a high likelihood of poor healing 
after repair surgery. 
Research question 
In patients with irreparable rotator cuff tears, how safe and effective is hu-
man dermal allograft compared to rotator cuff tear repair without augmenta-
tion concerning pain, range of motion, physical functioning, health-related 
quality of life and patient satisfaction, adverse events, re-tears, re-operations 
and procedure-related mortality? 
 
Methods 
A systematic review was conducted to investigate the safety and effectiveness 
of human dermal allograft. Four biomedical databases (Medline, Embase, the 
Cochrane Library, the University of York Centre for Reviews and Dissemi-
nation) were searched from inception to 14 December 2018. After deduplica-
tion, overall 455 citations were identified, of which ten studies were included 
for data extraction and further analysis. Two authors independently conduct-
ed the study selection and quality appraisal (AS, SW), the first author con-
ducted study extraction into a pre-define table which was checked by the 
second author. 
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Domain effectiveness 
Critical outcomes used to evaluate the relative efficacy of human dermal allo-
graft included change in pain scores (e.g., VAS, OSS, UCLA), change in range 
of motion scores (e.g., WORC, CS, ASES, ROM), change in physical function 
scores (e.g., CS, WORC, OSS, ASES), and change in health-related quality of 
life (HR-QoL) scores (e.g., WORC, OSS, SF-12). 
Domain safety 
Critical outcomes used to evaluate the relative safety of human dermal allo-
graft included procedure-related mortality, failure/re-tears, re-operation/ad-
ditional surgery, complications, and adverse events. 
 
Results 
Available evidence 
Only prospective studies with 20 or more patients and at least two years of 
follow-up were considered for inclusion in the assessment of efficacy. Clini-
cal studies with any patient number and follow-up period were considered for 
inclusion in the assessment of safety. One randomised controlled trial (n=42) 
was identified which investigated rotator cuff repair using human dermal 
allograft against the same procedure without human dermal allograft. This 
randomised control trial was funded by the manufacturer of GraftJacket. In 
addition, two non-randomised controlled trials (n=26; n=35) and seven sin-
gle arm studies (total n=277) were identified. 
Clinical effectiveness 
In the included controlled studies pain, range of motion, physical function 
and HR-QoL were assessed via several tools, including the CS, ASES, UCLA, 
OSS and WORC scores. Of all scores only the total scores have been report-
ed and not the sub-scales, thus only the total scores are reported once for all 
outcomes. 
Across the included controlled studies and scores some significant improve-
ments in pain, range of motion, physical functioning and HR-QoL could be 
identified. 
For example, using the VAS score the mean difference between groups in a 
non-randomised controlled trial (n=35) was calculated to be 2.7 points lower 
in the intervention group with the VAS (C: 6.9 [SD 1.1] vs 4.1 [SD 1.1]; I: 6.8 
[SD 1.6] vs 1.3 [SD 1.2]; p=0.024), which indicates a significant pain reduc-
tion in the treatment group. 
And, using the WORC score the mean difference in the same non-random-
ised controlled trial (n=35) was calculated to be 22.0 points higher compared 
to the control group, measured preoperatively and then at last follow-up (C: 
58.0 [SD 5.0] vs 66.0 [SD 5.0]; I: 54.0 [SD 8.0] vs 84.0 [SD 4.0]; p=0.0412), 
indicating a significant improvement in HR-QoL. HR-QoL was measured in 
the same study (n=35) using SF-12 and a non-significant improvement in the 
intervention group was reported. 
Other than the significant improvement in pain as measured using VAS and 
HR-QoL using WORC, all efficacy outcomes were found to have a consistent, 
but non-significant improvement across the scores and studies. 
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Safety 
No procedure-related mortality was reported in any of the included studies. 
The relative failure rates in the randomised controlled trial (n=42) were 45.0% 
(9/20) in the control group versus 13.6% (3/22) in the intervention group at 
mean follow-up of 24 months. Relative failure rates in a non-randomised con-
trolled trial (n=35) were 27.0% (4/15) in the control group versus 10.0% (2/20) 
in the intervention group at mean follow up of 24.9 months. The failure rate 
across the seven case series was 19.0% (24/126) with follow up times ranging 
from 12 to 77 months. 
No re-operation/additional surgery was reported in the randomised controlled 
trial. Re-operation rates in a non-randomised controlled trial (n=35) were 
26.0% (3/15) in the control group versus 10.0% (2/20) in the intervention 
group at mean follow up of 24.9 months. The total re-operation rate across 
five case series was 18.0% (14/78) with follow up times ranging from 12 to 39 
months. 
Complications were reported in six included studies, including a total of 192 
patients and mean follow-up times from 12 to 36 months. Only one study re-
ported a complication. It was a non-randomised controlled trial (n=35) which 
reported one patient had a skin infection after the procedure that was resolved 
with antibiotics. 
Adverse events were reported in five studies. Three single arm studies (n=47) 
reported none occurred and two studies, the randomized controlled trial (n= 
42) and one case series (n=9), reported 22 adverse events in total, resulting 
in a combined adverse event rate of 19.3% (22/114). Events include re-tears 
(12), cellulitis (2), shoulder bursitis (2), fibrosis (1), bicep tendon rupture (1), 
and subsequent shoulder injuries (4). No events were attributed to the pres-
ence of the human dermal allograft. 
Severe adverse events were not reported in the comparative studies. Two 
single arm studies, with mean follow up times from 12 to 15 months, report-
ed that no serious adverse events occurred, resulting in a combined severe 
adverse event rate of 0.0% (0/22). 
Quality of evidence 
Overall, the quality of evidence for the effectiveness and safety of surgical 
repair with human dermal allograft in comparison to surgical repair without 
human dermal allograft is considered “moderate”. 
Upcoming evidence 
Ongoing trials include four randomised controlled trials and one non-ran-
domised controlled trial. Completion dates are before mid-2020. Including a 
total of 244 patients, they investigate rotator cuff repair using human dermal 
allograft against the same procedure without a graft. Once these have been 
completed and published results are available, the evidence on human der-
mal allograft is expected be greatly strengthened. 
Reimbursement 
Currently, human dermal allografts (GraftJacketTM and Arthrex Inc.) are not 
included in the Austrian hospital benefit catalogue, thus the device is not re-
imbursed by the Austrian healthcare system. 
 
no morality cases 
reported 
 
failure rates 27.0-45.0% 
vs. 10.0-13.6% in  
2 controlled studies, 
failure rate across  
7 case series: 19.0% 
re-operation rate in  
1 N-RCT: 26.0 vs. 10.0%, 
re-operation rate across 
5 case series: 18.0% 
1 complication in 192 pts. 
(6 studies) reported, the 
1 complication reported 
in a N-RCT 
zero adverse events 
reported in 3 single arm 
studies (n=47),  
22 adverse event cases 
(19.3%) reported in  
RCT + 1 single arm study 
(n= 42 + 9) 
no severe adverse 
events reported 
overall, moderate 
quality of evidence 
4 ongoing RCTs +  
1 ongoing N-RCT 
(n=244), completion 
dates before mid-2020 
human dermal  
allografts currently not 
reimbursed in Austria  
Human dermal allograft for massive rotator cuff tears 
10 LBI-HTA | 2019 
Discussion 
There is a paucity of objective, randomised controlled studies to allow the 
assessment of the relative risks and benefit of rotator cuff tear repair with 
human dermal allograft in comparison to rotator cuff tear repair alone. 
The main limitations in the evidence base were related to small sample siz-
es, a lack of comparative data, and short follow-up durations. In addition, 
the randomised controlled trial was sponsored by the manufacturer of Graft-
Jacket. 
 
Conclusion 
At present, the evidence is insufficient to prove the technology is significant-
ly more effective and safer than the comparator. However, from the limited 
evidence, of “moderate” quality, it appears rotator cuff tear repair with hu-
man dermal allograft is more effective, and as safe as or even safer as its 
comparator. These findings should be considered with caution. 
It is recommended this technology be re-evaluated in 2021, when some of the 
ongoing trials have published results. 
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Zusammenfassung 
EinleitungIndikation und therapeutisches Ziel 
Der Fokus der vorliegenden Übersichtsarbeit liegt auf PatientInnenen mit 
irreparablen Rissen der Rotatorenmanschettensehnen. Die Rotatorenman-
schette besteht aus mehreren Muskeln mit Sehnen, die die Schulter stabili-
sieren. Wenn eine oder mehrere der Sehnen entweder aufgrund eines Trau-
mas oder aufgrund einer normalen Abnutzung gerissen sind, verspürt der Pa-
tient/die Patientin Schmerzen und eine eingeschränkte Bewegung des Arms. 
Ein Sehnenriss in der Rotatorenmanschette kann durch eine Operation re-
pariert werden. Es können jedoch erneute Risse postoperativ auftreten. Ein 
irreparabler Sehnenriss in der Rotatorenmanschetten wird als groß (>3 cm) 
bzw. massiv (>5 cm) definiert und umfasst den Riss von zwei bzw. mehreren 
Sehnen oder ein Sehnenriss bei dem eine primäre Operation erfolglos blieb. 
Ungefähr 30,0 % der PatientInnen mit Rotatorenmanschettensehnenrisse 
können nach der primären operativen Reparatur schwere irreparable Risse 
bzw. in 20,0 bis 90,0 % postoperative Risse aufweisen. 
Beschreibung der Technologie 
Humane Dermis kann als eine Art Augmentationstransplantat verwendet 
werden und bei der Sehnenreparatur der Rotatorenmanschette in den mus-
kulotendinösen Knochenkomplex eingebaut werden, wodurch die Fixierung 
der Sehnenrisse verbessert werden kann. Während Transplantate normaler-
weise aus tierischen Geweben (Xenograft) stammen oder künstlich mit syn-
thetischen Materialien hergestellt werden, wird für die Augmentation mit-
tels humaner Dermis Gewebe von Menschen – in diesem Fall Kadaverspen-
den – verwendet. 
Bei der überlegenen Kapselrekonstruktionstechnik (engl. superior capsular 
reconstruction, SCR) wird allogene humane Dermis verwendet. Diese Tech-
nologie soll eine verbesserte Konsistenz des Transplantats vorweisen und die 
Wahrscheinlichkeit von Komplikationen oder Misserfolgen des Verfahrens 
verringern. Die Transplantation von allogener humaner Dermis ist insbeson-
dere für RisikopatientInnen mit Sehnenrissen in der Rotatorenmanschette, 
für die die Heilungschancen nach einer Reparaturoperation niedrig sind, ge-
dacht, 
Forschungsfrage 
Wie sicher und wirksam ist die Transplantation von humaner Dermis bei 
PatientInnen mit irreparablen Rotatorenmanschettensehnenrissen im Ver-
gleich zur Rotatorenmanschettenreparatur ohne Augmentation in Bezug auf 
Schmerzen, Bewegungsumfang, körperliche Funktionalität, gesundheitsbe-
zogene Lebensqualität und PatientInnenzufriedenheit, sowie bezüglich ein-
griffsbedingter Mortalität, Fehlerquote, Komplikationen und Nebenwirkun-
gen? 
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Methoden 
Eine systematische Literatursuche wurde durchgeführt, um die Sicherheit 
und Wirksamkeit der Transplantation mittels allogener humaner Dermis zu 
untersuchen. Bis zum 14. Dezember 2018 wurden vier biomedizinische Da-
tenbanken (Medline, Embase, Cochrane Library, University of York Center 
für Reviews und Dissemination) durchsucht. Nach Deduplizierung konnten 
insgesamt 455 Zitate identifiziert werden, von denen zehn Studien für die 
Datenextraktion und weitere Analyse eingeschlossen wurden. Zwei Autorin-
nen führten die Studienauswahl und Qualitätsbeurteilung der Studien unab-
hängig voneinander durch (AS, SW). Die Erstautorin extrahierte die Studi-
endaten mit Hilfe einer vordefinierten Tabelle, die von der zweiten Autorin 
überprüft wurde. 
Klinische Wirksamkeit 
Zu den kritischen Endpunkten, die zur Beurteilung der relativen Wirksam-
keit von allogener humaner Dermis verwendet wurden, zählten die Verände-
rung der Schmerzwerte, gemessen anhand von drei Scores (VAS, OSS, UCLA), 
die Veränderung des Bewegungsumfanges, gemessen anhand von vier Scores 
(WORC, CS, ASES, ROM) und die Veränderung der körperlichen Funktio-
nalität, gemessen anhand von vier Scores (CS, WORC, OSS, ASES), sowie 
Änderung der gesundheitsbezogenen Lebensqualität, gemessen anhand von 
drei Scores (WORC, OSS, SF-12). 
Sicherheit 
Zu den kritischen Endpunkten, die zur Bewertung der relativen Sicherheit 
von allogener humaner Dermis verwendet wurden, gehörten die eingriffsbe-
dingte Mortalität, Technologieversagen/Rückfälle (Fehlerquote), Re-operati-
onen/zusätzliche Operationen, Komplikationen und unerwünschte Ereignisse. 
 
Ergebnisse 
Verfügbare Evidenz 
Lediglich prospektive Studien mit 20 oder mehr PatientInnen und einer 
Nachbeobachtungszeit von mindestens zwei Jahren wurden in die Bewertung 
der Wirksamkeit einbezogen. Bei der Auswahl der Studien für die Bewertung 
der Sicherheit wurden keine Restriktionen berücksichtigt. Es wurde eine ran-
domisierte kontrollierte Studie (n=42) identifiziert, in der die Reparatur der 
Rotatorenmanschettensehne mittels allogener humaner Dermis im Vergleich 
zu einem Verfahren ohne allogene humane Dermis untersucht wurde. Diese 
randomisierte Kontrollstudie wurde vom Hersteller der Technologie, Graft-
Jacket, gesponsert. Zusätzlich wurden zwei nicht randomisierte kontrollierte 
Studien (n=26; n=35) und sieben Einzelarmstudien (insgesamt n=277) iden-
tifiziert. 
Klinische Wirksamkeit 
In den eingeschlossenen kontrollierten Studien wurden Schmerz, Bewegungs-
umfang, körperliche Funktionsfähigkeit und gesundheitsbezogene Lebens-
qualität mit Hilfe von verschiedenen Scores bewertet. Für alle Scores wurden 
nur die Gesamtwerte und nicht die Subskalen berichtet. Aus diesem Grund 
wurden lediglich die Gesamtwerte der Scores für die jeweiligen Endpunkte 
angegeben. 
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Insgesamt zeigten die eingeschlossenen kontrollierten Studien für alle Scores 
(teilweise signifikante) Verbesserungen in Bezug auf Schmerzen, Bewegungs-
umfang, körperliche Funktionalität und gesundheitsbezogene Lebensqualität. 
Beispielsweise wurde in einer nicht randomisierten Studie (n=35) signifikan-
te VAS Scores berichtet, die die Berechnung eines durchschnittlichen Unter-
schieds von 2.7 Punkten zwischen den Studiengruppen ergab (C: 6.9 [SD 1.1] 
vs. 4,1 [SD 1.1]; I: 6,8 [SD 1.6] vs. 1,3 [SD 1.2]; p = 0.024). Dies bedeutet, 
dass sich die VAS Werte vom Zeitpunkt null bis zum letzten Follow-up in 
der Interventionsgruppe um 2,7 Punkte mehr reduziert haben als in Kon-
trollgruppe. Da niedrigere VAS Werte auf eine Schmerzreduktion verweisen, 
konnte für die Interventionsgruppe eine signifikante Schmerzverbesserung 
berichtet werden. 
Für dieselbe nicht randomisierte kontrollierte Studie (n=35) wurde im Hin-
blick auf die WORC-Scores ein durchschnittlicher Unterschied von +22,0 
Punkten im Vergleich zur Kontrollgruppe berechnet (C: 58.0 [SD 5.0] vs. 66,0 
[SD 5.0]; I: 54,0 [SD 8.0] vs. 84,0 [SD 4.0]; p = 0.0412). Diese Verbesserung 
der WORC-Scores in der Interventionsgruppe weist auf eine signifikante Ver-
besserung der Lebensqualität in dieser Studiengruppe hin. In derselben Stu-
die wurde die Lebensqualität mittels des SF-12 Scores gemessen, welches 
ebenso eine Verbesserung der Lebensqualität in der Interventionsgruppe – 
jedoch nicht statistisch signifikant – ergab. 
Abgesehen von der signifikanten Verbesserung der Schmerzen resultierend 
aus der VAS-Bewertung und der signifikanten Verbesserung der Lebensqua-
lität gemessen mit dem WORC-Score, ergaben die verbleibenden Messungen 
keine statistisch signifikanten Verbesserungen in den Interventionsgruppen. 
Sicherheit 
In keiner der eingeschlossenen Studien wurden Fälle zur eingriffsbedingten 
Mortalität berichtet. 
Die relativen Fehlerquoten in der randomisierten kontrollierten Studie (n= 
42) betrugen 45,0 % (9/20) in der Kontrollgruppe versus 13,6 % (3/22) in der 
Interventionsgruppe bei einer mittleren Nachbeobachtungszeit von 24 Mo-
naten. Die relative Fehlerquote in einer nicht randomisierten, kontrollierten 
Studie (n=35) betrug 27,0 % (4/15) in der Kontrollgruppe versus 10,0 % 
(2/20) in der Interventionsgruppe bei einem durchschnittlichen Follow-up 
von 24,9 Monaten. Die Fehlerquote der sieben Fallserien betrug 19,0 % (24/ 
126) bei einem Nachbeobachtungszeitraum zwischen 12 und 77 Monaten. 
In der randomisierten kontrollierten Studie wurden keine Re-Operationen 
berichtet. Die Re-Operationsrate in einer nicht randomisierten kontrollier-
ten Studie (n=35) lag in der Kontrollgruppe bei 26.0 % (3/15) gegenüber 
10.0 % (2/20) in der Interventionsgruppe bei einer durchschnittlichen Nach-
beobachtungszeit von 24.9 Monaten. Die Re-Operationsrate in fünf Fallse-
rien betrug 18.0% (14/78) bei einem Nachbeobachtungszeitraum von 12 bis 
39 Monaten. 
In sechs eingeschlossenen Studien mit insgesamt 192 PatientInnen und ei-
ner durchschnittlichen Nachbeobachtungszeit zwischen 12 und 36 Monaten 
wurden über Komplikationen berichtet: Lediglich in einer von den sechs 
Studien – in der nicht randomisierten kontrollierten Studie (n=35) – trat bei 
einem Patienten/einer Patientin eine Komplikation auf. Diese Person erlitt 
postoperativ eine Hautinfektion, die mit Antibiotika behandelt werden konn-
te. 
teilweise signifikante 
Verbesserung der 
Wirksamkeit 
1 N-RCT: signifikante 
Verbesserung der 
Schmerzen in der 
Interventionsgruppe, 
gemessen mit dem  
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1 N-RCT: signifikante 
Verbesserung der 
Lebensqualität in der 
Interventionsgruppe, 
gemessen mit dem 
WORC-Score 
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aber nicht signifikante 
Verbesserungen in den 
Interventionsgruppen 
keine Mortalitätsfälle 
Fehlerquoten von  
27,0-45,0 % vs.  
10,0-13,6 % in  
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1 N-RCT: 26.0 vs. 10.0 %, 
Re-Operationsrate bei  
5 Fallserien: 18.0% 
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192 PatientInnen.  
(6 Studien) 
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In fünf Studien wurde über unerwünschte Ereignisse berichtet. Drei Einarm-
studien (n=47) berichteten, dass keine Nebenwirkungen aufgetreten waren, 
und zwei Studien – die randomisierte kontrollierte Studie (n=42) und eine 
Fallserie (n=9) – gaben insgesamt 22 unerwünschte Ereignisse an, was in 
einer kombinierten Nebenwirkungsrate von 19,3 % (22/114) resultiert. Zu 
den Nebenwirkungen zählten erneute Sehnenrisse nach dem Eingriff (12), 
Zellulitis (2), Schulter-Bursitis (2), Fibrose (1), Bizepssehnenruptur (1) und 
nachfolgende Schulterverletzungen (4). Keine der Nebenwirkungen konnte 
auf die Augmentation mittels allogener humaner Dermis zurückgeführt wer-
den. 
In den inkludierten Studien wurden keine schwerwiegenden unerwünschten 
Ereignisse berichtet.  
Qualität der Evidenz 
Insgesamt wird die Qualität der Evidenz für die Wirksamkeit und Sicher-
heit der chirurgischen Reparatur mittels allogener humaner Dermis im Ver-
gleich zur chirurgischen Reparatur ohne humaner Dermis als „moderat“ an-
gesehen. 
Laufende Studien 
Die aktuell laufenden Studien umfassen vier randomisierte kontrollierte Stu-
dien und eine nicht randomisierte kontrollierte Studie. Fertigstellungstermine 
werden auf Mitte 2020 geschätzt. Mit insgesamt 244 PatientInnen untersu-
chen die Studien die Wirksamkeit und Sicherheit der Reparatur der Rotato-
renmanschette mittels allogener humaner Dermis im Vergleich zum gleichen 
Verfahren ohne Transplantat. Die Veröffentlichung der Studiendaten wird 
weitere relevante Evidenz für die Reparatur von Sehnenrissen in der Rotato-
renmanschette mittels allogener humaner Dermis erbringen. 
Kostenerstattung 
Derzeit ist die Transplantation von allogener humaner Dermis (GraftJa-
cketTM und Arthrex Inc.) nicht im österreichischen Leistungskatalog enthal-
ten und wird daher vom österreichischen Gesundheitssystem nicht erstattet. 
 
Diskussion 
Aktuell gibt es keine objektiven, randomisierten kontrollierten Studien, um 
die relativen Risiken und den Nutzen der Rotatorenmanschettenreparatur 
mittels allogener humaner Dermis im Vergleich zur Rotatorenmanschetten-
reparatur ohne Augmentation beurteilen zu können. 
Limitationen der vorhandenen Evidenz umfassen kleine Stichprobengrößen, 
fehlende Vergleichsdaten und kurze Nachbeobachtungszeiträume. Darüber 
hinaus wurde die randomisierte kontrollierte Studie vom Hersteller von Graft-
Jacket gesponsert. 
 
  
keine unerwünschten 
Ereignisse in  
3 Einarmstudien (n=47), 
22 Nebenwirkungen 
(19,3 %) in 1 RCT +  
1 Einarmstudie 
(n=42 + 9) 
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4 laufende RCTs +  
1 laufende N-RCT 
(n=244), 
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fehlen 
Limitationen: kleine 
Stichprobengrößen, 
kurze Nachlaufzeiten 
usw. 
Zusammenfassung 
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Zusammenfassung/Empfehlung  
Auf der Grundlage der verfügbaren Evidenz können keine Schlussfolgerun-
gen gezogen werden, ob die Reparatur von Sehnenrissen in der Rotatoren-
manschette mittels allogener humaner Dermis wesentlich wirksamer und si-
cherer ist als eine Reparatur ohne Augmentation. Basierend auf der verfüg-
baren Evidenz von „mäßiger“ Qualität scheint die Reparatur mittels alloge-
ner humaner Dermis effektiver und genauso sicher oder sogar sicherer zu 
sein als ohne Augmentation. Aufgrund der limitierten Evidenz sollten diese 
Feststellungen jedoch mit Vorsicht betrachtet werden. 
Die erneute Bewertung wird im Jahr 2021 empfohlen, wenn weitere laufende 
Studien abgeschlossen sind und dadurch zusätzliche Evidenz vorliegt. 
 
 
gemäß aktueller 
Evidenz ist Transplantat 
mittels humaner Dermis 
wirksamer und gleich 
sicher oder sicherer 
erneute Bewertung  
für 2021 empfohlen 
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1 Scope 
1.1 PICO question 
In patients with irreparable rotator cuff tears, how safe and effective is human 
dermal allograft compared to rotator cuff tear repair without augmentation 
when concerning pain, range of motion, physical functioning, health-related 
quality of life, patient satisfaction, adverse events, re-tears, re-operations, and 
procedure-related mortality? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Population Patients with irreparable tears of the shoulder rotator cuff tendon.  
Contraindications/exclusions: Presence of subscapular tear, presence of glenohumeral 
osteoarthritis, Western Ontario Rotator Cuff (WORC) score >70%, uncontrolled diabetes, 
pregnancy, presence of local or systemic infection, paralysis of the shoulder, poor 
nutritional state, contracture of the shoulder, presence of cuff tear arthropathy,  
MRI proven nonvascular surgical sites, and cancer. 
MeSH Terms: Rotator Cuff Injury [C26.761.340, C26.803.063, C26.874.400] 
Rationale: Currently limited international guidelines on the recommended use of human 
dermal allograft for massive rotator cuff tears are available. Therefore, the population has 
been informed by a case series,[1] and a review article [2]. 
Intervention Reconstruction of the rotator cuff tear with human dermal allograft (athroscopic or open 
technique), e.g. superior capsular reconstruction (SCR), depending on the size and 
configuration of the tear.This is conducted in a revision setting after prior failed rotator 
cuff repairs. 
Product names: GraftJacket (Wright Medical Technology Inc. TN, USA);  
Arthrex ArthroFLEX Inc. FL, USA) 
MeSH Terms: Acellular dermis [A17.815.180.040] 
Rationale: The relevant intervention has been informed by review articles [3, 4]. 
Control Any surgical reconstruction of irreparable rotator cuff tears without  
use of human dermal allograf, e.g.: 
 Tendon transfer 
 Inverse arthroplasty 
Rationale: One randomised study was identified during scoping. In this study, rotator cuff 
tear repair procedure without human dermal allograft was the control intervention [5]. 
 
  
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
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Outcomes 
Efficacy Critical clinical endpoints include changes between pre- and post-treatment outcomes for: 
(A) pain, (B) range of motion, (C) physical function, (D) Health-Related Quality of Life 
Important clinical endpoints include changes between pre- and post- treatment outcomes 
for: (E) patient satisfaction and MRI scan of intact cuffs.  
These are measured with the following tools: 
 Western Ontario Rotator Cuff Index (WORC) questionnaire (B), (C), (D) 
 Disabilities of the arm, shoulder, and hand (DASH) score (A), (C) 
 Shoulder Pain and Disability Index (SPADI) score (A), (C) 
 Range Of Motion (ROM) score (B) 
 Subjective shoulder value (SSV) score (C)(E) 
 Constant shoulder (CS) assessment (A), (B), (C) 
 Oxford Shoulder Score (OSS) (A), (C), (D) 
 Visual analogue scale (VAS) score (A) 
 American Shoulder and Elbow Surgeons (ASES) score (A), (B), (C) 
 SF-12 score (D) 
 University of California, Los Angeles (UCLA) shoulder score (A), (B), (C), (E) 
Rationale: Efficacy outcomes were informed by a review article,[4] clinical studies, [1, 5] 
and the EUnetHTA guidelines [6, 7]. 
Safety  Procedure-related mortality 
 Failure of repair procedure/re-tears 
 Re-operation/additional surgery 
 Complications (procedure-related and device-related) 
 Adverse events (e.g. bursitis, cellulitis, & fibrosis) 
Rationale: Safety outcomes were informed by a randomised study,[5] and  
the EUnetHTA guidelines [8]. 
Study design 
Efficacy  Randomised controlled trials 
 Prospective non-randomised comparative study designs 
 In the absence of comparative evidence, prospective case series with ≥ 20 participants 
and at least 48 months follow up will be included.  
Excluded: case studies, review articles, conference abstracts, letter to the editor,  
author response, retrospective case series. 
Safety  Randomised controlled trials 
 Prospective non-randomised controlled trials 
 Prospective case series  
 Retrospective case series 
Excluded: case studies, review articles, conference abstracts, letter to the editor,  
author response. 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What is a human dermal allograft and the comparator(s)? 
A0020 For which indications has human dermal allograft received marketing authorisation  
or CE marking? 
B0002 What is the claimed benefit of human dermal allograft in relation to the comparators? 
B0003 What is the phase of development and implementation of human dermal allograft  
and the comparator(s)? 
B0004 Who administers human dermal allograft and the comparators and in what context  
and level of care are they provided? 
B0008 What kind of special premises are needed to use human dermal allograft  
and the comparator(s)? 
B0009 What supplies are needed to use human dermal allograft and the comparator(s)? 
A0021 What is the reimbursement status of human dermal allograft? 
 
Health problem and Current Use 
Element ID Research question 
A0001 For which health conditions, and for what purposes is human dermal allograft used? 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for irreparable rotator cuff tears? 
A0004 What is the natural course of irreparable rotator cuff tears? 
A0005 What is the burden of disease for the patients with irreparable rotator cuff tears? 
A0006 What are the consequences of irreparable rotator cuff tears for the society? 
A0024 How are irreparable rotator cuff tears currently diagnosed according to published guidelines 
and in practice? 
A0025 How are irreparable rotator cuff tears currently managed according to published guidelines 
and in practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 How much are human dermal allografts utilised? 
 
Clinical Effectiveness 
Element ID Research question 
D0005 How does human dermal allograft affect symptoms and findings (severity, frequency)  
of irreparable rotator cuff tears? 
D0006 How does human dermal allograft affect progression (or recurrence) of irreparable  
rotator cuff tears? 
D0011 What is the effect of human dermal allograft on patients’ body functions? 
D0016 How does the use of human dermal allograft affect activities of daily living? 
D0012 What is the effect of human dermal allograft on generic health-related quality of life? 
D0013 What is the effect of human dermal allograft on disease-specific quality of life? 
D0017 Was the use of human dermal allograft worthwhile? 
Human dermal allograft for massive rotator cuff tears 
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Safety 
Element ID Research question 
D0001 What is the expected beneficial effect of human dermal allograft on mortality? 
D0003 What is the effect of human dermal allograft on the mortality due to causes  
other than irreparable rotator cuff tears? 
C0008 How safe is human dermal allograft in comparison to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying human dermal allograft? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through  
the use of human dermal allograft? 
C0007 Are human dermal allograft and comparator(s) associated with user-dependent harms? 
B0010 What kind of data/records and/or registry is needed to monitor the use  
of human dermal allograft and the comparator? 
 
 
2.2 Sources 
Description of the technology 
 Hand-search in the Planned Ongoing Projects database (POP), 
AdHopHTA and CRD databases for Health Technology Assessments 
 Background publications identified in database search: see Section 2.3 
 Questionnaire completed by the submitting hospitals 
Health problem and Current Use 
 Hand-search in the POP, AdHopHTA and CRD databases  
for Health Technology Assessments 
 Background publications identified in database search: see Section 2.3 
 Questionnaire completed by the submitting hospitals  
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Quellen: systematische 
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Einreicher 
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2.3 Systematic literature search 
The systematic literature search was conducted on the 14.12.2018 in the  
following databases:  
 Medline via Ovid (including PubMed) 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
The systematic literature search was conducted in The Cochrane Library, 
York CRD, Medline and Embase from inception to 14 December 2018 for 
only prospective or randomised controlled trials and restricted to articles 
published in English or German. The specific search strategies employed are 
presented in the Appendix. 
Following a hand-search, three additional studies were found, resulting in 
overall 455 hits. 
No publications were submitted by the responsible hospitals. 
Both manufacturers have been contacted, however, none of the manufactur-
ers replied. Thus, no additional publication have been submitted. 
Furthermore, to identify ongoing and unpublished studies, a search in three 
clinical trials registries (ClinicalTrials.gov; WHO-ICTRP; EU Clinical Trials) 
was conducted on the 11.01.2019. This search identified 67 results of which 
five trials (4 randomised controlled trials and 1 non-randomised controlled 
trial) were deemed recent and relevant to this assessment, see Table A-10 & 
Table A-11.  
 
  
systematische 
Literatursuche in  
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systematische Suche 
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keine Studien  
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2.4 Flow chart of study selection 
Overall, after removal of duplicates, 455 records were identified. These were 
screened by two independent researchers and in case of disagreement, they 
resolve the differences via discussion. The selection process is displayed in 
Figure 2-1. 
 
Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
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2.5 Analysis 
The data retrieved from the selected studies (see Chapter 2.4) were systemat-
ically extracted into data-extraction-tables (see Appendix). Data were ex-
tracted by a single author and checked by the second author. No quantita-
tive analysis was conducted due to the limited amount of evidence. Risk of 
bias was assessed using Cochrane Risk of Bias tool for the randomised con-
trolled trial [9], ROBINS-I for non-randomised controlled trials [10], and 
the Institute of Health Economics (IHE) Checklist for case series studies [11] 
(see Table A-3, Table A-4, Table A-5).  
 
 
2.6 Synthesis 
The questions were answered in plain text format with reference to Grading 
of Recommendations Assessment, Development and Evaluation (GRADE)  
evidence tables [12] that are included in Appendix. As comparative studies 
did not conduct any significant testing between groups, we calculated the 
mean difference between time points. Results were summarised in Table 7-1. 
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Cochrane RoB-Tool, 
ROBINS-I und  
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Evidenzsynthese  
mittels GRADE 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What is a human dermal allograft and the comparator (s)? 
Technology – Surgical treatment of irreparable rotator cuff tear  
with human dermal allograft 
Human dermal allografts are most commonly used in the superior capsule  
reconstruction (SCR) technique [13]. The procedure is a replacement sur-
gery for the torn rotator cuff tendon with incorporation of the human dermal  
allograft. Patients lie on their side under general anaesthesia and a number 
of portals are established for inserting of the arthroscope. The human der-
mal allograft is then arthroscopically secured between the superior glenoid 
neck, intact rotator cuff, greater tuberosity, and the rotator interval tissue 
[13, 14]. 
The products presently available on the market are GraftJacket® which is 
manufactured by Wright Medical Group Inc. and ArthroFLEX® manufac-
tured by Arthrex. Differences between the two products are outlined in Ta-
ble 3-1. 
Table 3-1: Features of human dermal allograft products on the market 
Product Features 
ArthroFLEX  Available in in 11 shapes/sizes/thicknesses 
 Sterile, with a Sterility Assurance Level of 10-6 
 Decellularized >97% DNA and cellular remnants  
removed using MatrACELL® process 
 Intact acellular extracellular matrix 
 Pre-hydrated, water packed 
 3-year shelf life at room temperature 
GraftJacket  Available in in 9 shapes/sizes/thicknesses 
 Sterile, with a Sterility Assurance Level of 10-6 
 Decellularized with DNA and cellular remnants removed 
 Intact acellular extracellular matrix 
 Pre-hydrated, water packed 
 2-year shelf life at room temperature 
 
Comparator – Surgical treatment of irreparable rotator cuff tear  
without human dermal allograft 
The comparator for this intervention is surgical reconstruction of irreparable 
rotator cuff tears without the use of human dermal allograft. This includes: 
 Tendon transfer or inverse arthroplasty 
 The above surgical procedures using augmentation  
with animal-derived or synthetic grafts 
Rekonstruktion  
der irreparablen 
Rotatorenmanschette 
mittels Anbringung 
allogener humaner 
Dermis 
2 Produkte von  
2 unterschiedlichen 
Herstellern 
Unterschiede der  
beiden Produkte 
Reparatur OHNE 
allogener humaner 
Dermis,  
z. B. Sehnentransfer, 
Arthroplastik, etc. 
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The procedure for repairing rotator cuff tear without augmentation is de-
scribed by American Academy of Orthopaedic Surgeons (AAOS) [15], this ap-
proach is more common in reparable tears.  
Regular rotator cuff tear surgical procedures can be arthroscopic or open. 
Open surgical incision is required if the tear is long or complex. The surgeon 
often detaches the deltoid to gain better access, one or more bone spur may 
be removed from the underside of the acromion; this is also done when addi-
tional reconstruction, such as tendon transfers, is being conducted.  
In arthroscopic repair, an arthroscope is inserted into the shoulder joint 
through small incisions and the repair is carried out. Arthroscopic repair is 
usually an outpatient procedure. 
Another technique is the mini-open repair. This involves a small incision ap-
proximately 3-5 cm in length. This approach uses arthroscopy to treat dam-
age and remove bone spurs. However, differences include the deltoid being 
detached and repair is not being viewed through a screen by the surgeon [15]. 
Massive rotator cuff tear have an increased likelihood of re-tear and in recent 
years newer methods of repair have been sought. Reverse shoulder arthroplas-
ty and tendon transfer have been performed on these rotator cuff tears; how-
ever, high complication rates remain and long-term results are uncertain, par-
ticularly in younger patients [4]. 
Additional approaches include arthroscopic partial repair and arthroscopic 
debridement; both have success rates of around 50.0% [16].  
Irrespective of the advances and the development of novel treatment types the 
best practice for irreparable rotator cuff tear is agreed to be SCR [4]. There-
fore, SCR using fascia lata autograft without human dermal allograft augmen-
tation is seen as the primary comparator in this investigation. 
A0020 – For which indications has human dermal allograft  
received marketing authorisation or CE marking? 
The manufacturers of the two human dermal allograft products on the mar-
ket – Wright Medical Group Inc. and Arthrex Inc. – have not received mar-
keting authorisation for the products in any jurisdictions, including Europe. 
In general, human tissue donation is regulated in the European Union under 
the European Union Tissue and Cells Directives (EUTCD) 2004/23/EC. The 
EUTCD outlines the legal framework for the supply of tissues and cells with-
in the EU, to ensure that biological samples meet acceptable safety and qual-
ity standards. In this regard, individual suppliers of tissue samples that are 
licensed to distribute tissue samples under the EUTCD can distribute with-
in the European Union. 
B0002 – What is the claimed benefit of human dermal allograft  
in relation to the comparators? 
Human dermal allograft is intended to treat patients with massive, irrepara-
ble rotator cuff tears, by improving function, reducing pain and preventing 
re-tears [17-19]. Specifically, human dermal allograft is proposed as a supe-
rior technique leading to improvement in pain, range of motion, and strength 
as well as mechanical improvement in ultrasound imaging at follow up [20]. 
The submitting hospital did not propose a specific clinical claim in relation 
to an appropriate comparator, rather that there is no alternative technique 
that achieves successful, long-lasting, repair in the intended patient group. 
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B0003 – What is the phase of development and implementation of 
human dermal allograft and the comparator(s)? 
No evidence was identified that could be used in the examination  
of this question. 
 
Administration, Investments, personnel and tools  
required to use the technology and the comparator(s) 
B0004 – Who administers human dermal allograft and the 
comparator(s) and in what context and level of care are they provided? 
B0008 – What kind of special premises are needed to use human  
dermal allograft and the comparator(s)? 
Rotator cuff repair using an acellular human dermal allograft should be per-
formed by an orthopaedic surgeon that is fellowship trained in arthroscopic 
surgery of the shoulder. For the intervention, an orthopaedic surgeon expe-
rienced in the use of human dermal allograft will be preferred. Rotator cuff 
repair with and without human dermal allograft are performed with the pa-
tient under general anaesthesia. They should be conducted in a medical cen-
tre that is accustomed to performing arthroscopic rotator cuff repair, in a 
sterile operating theatre.  
B0009 – What supplies are needed to use human dermal allograft  
and the comparator(s)? 
During the procedure, several supplies are needed. The following steps are 
required to perform the surgical technique; the supplies needed are listed 
alongside the respective step: 
1. Preoperative workup 
2. Surgical positioning and diagnostic arthroscopy  
(padded arm sleeve, an ablation devices or curved scissors, cannulas) 
3. Superior glenoid neck preparation  
(an ablation device or arthroscopic shaver, anchors) 
4. Placement of medial anchors (postersuperior anchor) 
5. Graft sizing and preparation  
(acellular human dermal allograft, arthroscopic suture passer) 
6. Graft insertion and medial fixation 
7. Lateral graft fixation to humerus  
(corkscrew anchors, lateral-row anchors) 
8. Anterior and posterior edge fixation 
9. Closure [13]. 
 
Regulatory & reimbursement status  
A0021 – What is the reimbursement status of human dermal allograft? 
Currently, human dermal allografts (GraftJacketTM and Arthrex Inc.) are not 
included in the Austrian hospital benefit catalogue. Therefore, the device it-
self is not reimbursed by the Austrian healthcare system. However, the in-
tervention could be billed under another code, like for reconstruction of the 
capsule-ligament apparatus of the shoulder joint – arthroscopic (Code 
ME080 Rekonstruktion des Kapsel-Band-Apparates des Schultergelenks – 
arthroskopisch). 
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4 Health Problem and Current Use 
Overview of the disease or health condition 
A0001 – For which health conditions, and for what purposes is human 
dermal allograft used? 
Human dermal allograft can be used in a range of orthopaedic procedures, 
including hip & femur, knee, foot, soft tissue, thumb, elbow, shoulder, wrist, 
hand, or other musculoskeletal system procedures [21].  
It is proposed that human dermal allograft should be limited to rotator cuff 
tear patients with a high likelihood of poor healing after repair surgery. The 
most common indication for human dermal allograft augmentation is tears 
that are massive and that, while surgically repairable, they have a high risk 
of not healing [22].  
A0002 – What is the disease or health condition in the scope  
of this assessment? 
The rotator cuff is comprised of several muscles, including the supraspinatous 
muscle, infraspinatus muscle, teres minor muscle, and subscapularis muscle. 
The tendons of each muscle act together to stabilize the shoulder. 
When one of the rotator cuff muscles are torn, either following trauma or 
normal wear and tear, the patient experiences pain and restricted movement 
of the arm [23, 24]. 
Rotator cuff tear can usually be repaired with surgery. An irreparable rotator 
cuff tear is defined as large (>3 cm) or massive (>5 cm), involving two or 
more tendons, or one which has undergone primary surgery without success 
[18, 25]. 
The scope of the present assessment is patients with irreparable rotator cuff 
tears. 
A0003 – What are the known risk factors for irreparable  
rotator cuff tears? 
Rotator cuff tears can result from extrinsic trauma, such as falls and sport-
ing injuries, or may be gradually degenerative without any notable trauma. 
The aetiology is judged purely on patient reported history and is likely to be 
multi-factorial [26, 27]. 
Rotator cuff tears are more common in males, those engaged in heavy labour, 
and with a history of trauma [28]. Increased age is an important risk factor 
[22, 26]; indeed, it was reported 51% of individuals aged over 80 years had an 
asymptomatic rotator cuff tear in a study conducted on 411 German volun-
teers [29]. High cholesterol, history of smoking and genetics are also known 
risk factors for rotator cuff tear [27, 30]. 
A0004 – What is the natural course of massive rotator cuff tears? 
Rotator cuff tears have a limited ability to heal without surgical intervention. 
Tear progression is a significant risk and is correlated with symptom devel-
opment [27]. 
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A group of 45 asymptomatic patients were observed over a five-year period 
and 51.0% became symptomatic after 2.8 years. This was associated with in-
creased pain and decreased ability to perform actions of daily life (P<0.05) 
[31]. 
Risks associated with non-operative treatment in symptomatic patients in-
clude tear progression without spontaneous healing, increased difficulty with 
tendon mobilisation, fatty infiltration of the rotator cuff muscles, and pro-
gression to arthritis later in life [27]. 
 
Effects of the disease or health condition  
on the individual and society 
A0005 – What is the burden of disease for patients with  
irreparable rotator cuff tears? 
In general, rotator cuff tears have the potential to cause debilitating shoulder 
pain, reduced shoulder function, and compromised joint mechanics, leading 
to degeneration of the glenohumeral joint over time [32], and lowering qual-
ity of life. 
As stated, symptoms of rotator cuff tear may occur immediately after trauma 
(acute) or develop over time (chronic). 
Traumatic tears mostly affect the supraspinatus tendon, or the rotator inter-
val and symptoms include severe pain that radiates through the arm, and lim-
ited range of motion, specifically while lifting the shoulder. Symptoms aris-
ing from chronic tears include sporadic worsening of pain, debilitation, and 
atrophy of the muscles, pain during rest, crackling sensations when moving 
the shoulder, and an inability to move or lift the arm satisfactorily [33]. 
Irreparable rotator cuff tears have this same symptom profile, primarily dis-
tinguished by failure of repair surgery [34]. 
A0006 – What are the consequences of irreparable  
rotator cuff tears for the society? 
Cadaveric studies out of Japan and the United States have estimated the in-
cidence of rotator cuff tears in the general population to be between be 13.0% 
to 37.0% for partial-thickness tears and 7.0% to 27.0% for full-thickness tears 
[22]. 
One case series report that up to 30.0% of patients presenting with rotator 
cuff tears may have massive irreparable tears; further to that post-operative 
re-tear rates after primary surgical repair of rotator cuff tears range from 
20.0% to 90.0% [34]. 
Furthermore, a vast majority of the patients suffering from massive/ irrepa-
rable rotator cuff tears are in their productive age. As a result, a part of the 
patients might be incapacitated for work, which can be assumed to result in 
additional societal costs. 
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Current clinical management of the disease or health condition 
A0024 – How are irreparable rotator cuff tears currently diagnosed 
according to published guidelines and in practice? 
No guidelines for the diagnosis of irreparable rotator cuff tears could have 
been identified. According to Thorsness et. al (2016), upon physical examina-
tion, the surgeon will assess the presence of scars, range of motion, and con-
duct comprehensive neurovascular check. Massive tears involving the infra-
spinatus tendon will usually present with increasing passive internal rota-
tion. Massive tears involving the subscapularis tendon will usually present 
with increasing passive external rotation. The surgeon will also palpate the 
long head biceps and conduct strength testing of all rotator cuff muscles. 
Imaging for all patient with suspected rotator cuff tear will include true an-
teroposterior, axillary lateral, and outlet views of the shoulder. Although ultra-
sound can be used in tear diagnosis, magnetic resonance imaging is preferred 
as it enables estimation of the size, location, and chronicity of the tear [2]. 
A0025 – How are irreparable rotator cuff tears currently managed 
according to published guidelines and in practice? 
No guidelines for the treatment of irreparable rotator cuff tears could have 
been identified. According to Thorsness et. al (2016), options after failed re-
pair surgery include simple debridement with biceps tenotomy or tenodesis, 
revision repair with or without allograft augmentation, or SCR. It is the most 
popular method for irreparable rotator cuff tears, especially in younger pa-
tients [2]. 
 
Target population 
A0007 – What is the target population in this assessment? 
The population of this assessment includes patients with irreparable tears of 
the shoulder rotator cuff tendon. See the PICO criteria for further definition. 
A0023 – How many people belong to the target population? 
No information on the Austrian or European data for the prevalence or inci-
dence of irreparable rotator cuff tear was identified to inform this research 
question. Similarly, the frequency of repair surgery conducted for this popu-
lation in Austria is currently unknown. 
A0011 – How much are human dermal allografts utilised? 
The estimated annual utilisation of the submitting hospitals of human dermal 
allografts (athroscopic or open technique) in Austria is about 160 [informa-
tion of submitting hospitals 2018]. 
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5 Clinical effectiveness 
5.1 Outcomes 
The following outcomes were defined as critical to derive a recommendation 
on the clinical effectiveness of human dermal allograft repair: 
 Decrease in pain 
 Increase in range of motion 
 Increase in physical function 
 Increase in health-related quality of life 
Pain is the primary symptom that is used to measure the effectiveness of sur-
gical repair. It is most often measured using patient reported or observer-
reported questionnaire scales, and as such is difficult to measure objectively. 
Pain can be measured using generic scales, such as a Visual Analogue Scale 
(VAS), or disease-specific questionnaires, Oxford Shoulder Score (OSS), Uni-
versity of California, Los Angeles (UCLA) Score, American Shoulder and El-
bow Surgeons (ASES), and Constant Score (CS) assessment. 
Range of motion is a typical measure to assess shoulder pathology treatments. 
It measures patients’ ability to raise their arm above shoulder height. There 
are specific tools with sub-scales to measure it such as UCLA, ASES, CS and 
Western Ontario Rotator Cuff Index (WORC) assessment. 
Physical function is a measure of how the disease impacts daily life and ac-
tivities. It measures patients’ ability to complete tasks of daily life. It can be 
measured using sub-scales of a range of different scoring tools, including 
ULCA, ASES, CS, OSS and WORC assessment. 
Health-related quality of life (HR-QoL) can be measured using generic scales 
such as SF-12 or with sub-scales of specific shoulder scores, such as OSS and 
WORC index. 
The scales of the different scores are explained in more detail in the evidence 
tables in the Appendix. 
In addition to the critical outcomes, two additional outcomes  
were considered important but not crucial to the decision: 
 Patient satisfaction 
 MRI scan of intact cuffs. 
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5.2 Included studies 
To evaluate the effectiveness of human dermal allograft in rotator cuff repair 
surgery, we considered randomised controlled trials and prospective non-ran-
domised controlled trials comparing human dermal allograft to any surgical 
repair without using human dermal allograft. 
One randomised controlled trial [35], and two non-randomised controlled tri-
als [17, 18] met the pre-defined inclusion criteria. Investigators in two stud-
ies [17, 35] reported outcomes for the GraftJacket, and in one study [18] for 
the ArthroFLEX. 
The randomised controlled trial was a prospective institutional review board-
approved, multicentre series of patients randomised to undergo rotator cuff 
repair with human dermal allograft, or the same procedure without human 
dermal allograft.  
This study was supported by grants from the manufacturer, Wright Medical 
Technology. It was conducted in the United States and enrolled 42 patients 
with irreparable rotator cuff tear. From the total sample, 22 were randomised 
to receive human dermal allograft, and 20 to have the repair surgery without 
augmentation. All patients used an abduction sling for four to six weeks and 
started supervised physical therapy at four weeks post-operatively. 
Patients had a mean age of 56 years (range, 34 to 72 years). Most patients were 
male, with four (18.2%) females in the intervention group, and seven (35.0%) 
females in the control group. Mean patient follow up was 24 months, rang-
ing from 12 to 38 months. Losses to follow up were not reported. 
The two non-randomised controlled trials also studied patients undergoing 
repair with or without human dermal allograft augmentation. One non-ran-
domised prospective blinded trial [18] was conducted in the United States 
with ArthroFLEX as the intervention. The second non-randomised prospec-
tive controlled trial [17] was conducted in the United Kingdom with Graft-
Jacket as the intervention. 
The trials included a total of 61 patients with irreparable rotator cuff tear. 
There were 33 patients receiving surgical repair with human dermal allograft 
and 28 receiving surgical repair with no human dermal allograft, across stud-
ies. All groups had an abduction sling for six weeks and started supervised 
physical therapy at similar time points post-operatively. 
The mean age of patients ranged from 57 to 59 in the intervention groups and 
from 59 to 62 in the control groups across studies. Between four (30.1%) and 
twelve (40.0%) of the patients in the intervention groups and between four 
(30.1%) and eight (53.0%) of the patients in the control group were females 
across studies. 
The mean follow up time of the studies was 24 and 24.9 months, with ranges 
from 22 months to 60 months. 
Study characteristics and results of included studies are displayed in Table 
A-1 and Table A-2 and in the evidence profile in Table A-7. 
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5.3 Results 
Morbidity 
D0005 – How does human dermal allograft affect symptoms  
and findings (severity, frequency) of irreparable rotator cuff tears? 
The critical outcomes for efficacy were pain, range of motion, HR-QoL, and 
physical function. In the included controlled studies, pain, range of motion 
and physical function were assessed via several tools, including the CS, ASES, 
UCLA, OSS and WORC scores. Of all scores only the total scores have been 
reported and not the sub-scales, thus only the total scores are reported once 
for all outcomes. 
In the RCT [35], the CS mean difference was calculated to be 11.4 points 
higher in the intervention group, preoperatively versus last follow-up (C: 45.8 
vs 85.3 [SD 11.0]; I: 41.0 vs 91.9 [SD 9.2]; p=0.008). The ASES score mean 
difference was calculated to be 1.6 points higher in the intervention group, 
preoperatively versus last follow-up (C: 46.0 vs 94.8 [SD 14.2]; I: 48.5 vs 98.9 
[SD 4.2]; p=0.035). The UCLA shoulder score mean difference was calculat-
ed to be 2.5 points higher in the intervention group, preoperatively versus last 
follow-up (C: 15.9 vs 28.3 [SD -3.0]; I: 13.3 vs 28.2 [SD 2.1]; p=0.43). 
One non-randomised controlled trial [17] had a calculated mean difference in 
CS assessment of 15.0 points higher in the intervention group, preoperative-
ly versus last follow-up (C: 43.1 [SD 3.9] vs 70.8 [SD 5.3]; I: 41.2 [SD 3.1] vs 
83.9 [SD 6.0]; p<0.01). Additionally, the mean difference in OSS assessment 
was calculated to be 9.7 points higher in the intervention group, preoperative-
ly versus last follow-up (C: 17.8 [SD 3.6] vs 37.1 [SD 2.4]; I: 14.9 [SD 3.5] vs 
43.9 [SD 2.4]; p=0.01). 
The other non-randomised controlled trial [18] had a mean difference calcu-
lated to be 12.8 points higher than controls with the ASES scale, preoperative-
ly versus last follow-up (C: 60.3 [SD 9.5] vs 72.6 [SD 11.9]; I: 63.8 [SD 13.8] 
vs 88.9 [SD 4.8]; p=0.024). Also the mean difference was calculated to be 22.0 
points higher for the intervention group in the WORC assessment, preoper-
atively versus last follow-up (C: 58.0 [SD 5.0] vs 66.0 [SD 5.0]; I: 54.0 [SD 8.0] 
vs 84.0 [SD 4.0]; p=0.0412). In addition, the mean difference was calculated 
to be 2.7 points lower in the intervention group with the VAS (C: 6.9 [SD 1.1] 
vs 4.1 [SD 1.1]; I: 6.8 [SD 1.6] vs 1.3 [SD 1.2]; p=0.024), which indicates a 
significant pain reduction in the treatment group. 
Overall, across the included controlled studies and scores a partly significant 
improvement in pain, range of motion and physical functioning could be iden-
tified. 
For results of the assessment of HR-QoL see research question “D0012 – What 
is the effect of human dermal allograft on generic health-related quality of 
life?” in this section. 
D0006 – How does human dermal allograft affect progression  
(or recurrence) of irreparable rotator cuff tears? 
For information on device failures see Section 6.3 research question “C0008 
– How safe is human dermal allograft in comparison to the comparator(s)?”. 
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Function 
D0011 – What is the effect of human dermal allograft  
on patients’ body functions? 
D0016 – How does the use of human dermal allograft affect  
activities of daily living? 
Physical function was assessed by five scores (ULCA, ASES, CS, OSS and 
WORC) across three studies [17, 18, 35]. For all scores only total scores have 
been reported in the studies but not the sub-scale for physical functioning. 
The ULCA score was calculated to have a mean difference of 2.5 points high-
er in the intervention group of the randomised controlled trial [35], preoper-
atively versus last follow-up (C: 15.9 vs 28.3, [SD -3.0]; I: 13.3 vs 28.2, [SD 
2.1]; p=0.43). 
The ASES score was calculated to have a mean difference of 1.6 points high-
er for the intervention group in the randomised controlled trial [35], preoper-
atively versus last follow-up (C: 46.0 vs 94.8 [SD 14.2]; I: 48.5 vs 98.9 [SD 4.2]; 
p=0.035). The ASES score mean difference was calculated to be 12.8 points 
higher in the intervention group of a non-randomised controlled trial [18], pre-
operatively versus last follow-up (C: 60.3 [SD 9.5] vs 72.6 [SD 11.9]; I: 63.8 
[SD 13.8] vs 88.9 [SD 4.8]; p=0.024). 
The total CS assessment mean difference was calculated to be 11.4 points 
higher for the intervention group in the randomised controlled trial [35], pre-
operatively versus last follow-up (C: 45.8 vs 85.3, [SD 11.0]; I: 41.0 vs 91.9, 
[SD 9.2]; p=0.008). A mean difference of 15.0 points higher was calculated in 
the intervention group of a non-randomised controlled trial [17], preopera-
tively versus last follow-up (C: 43.1 [SD 3.9] vs 70.8 [SD 5.3]; I: 41.2 [SD 3.1] 
vs 83.9 [SD 6.0]; p<0.01). 
The same non-randomised controlled trial [17] reported the OSS score with 
the mean difference was calculated to be 9.7 points higher in the intervention 
group (C: 17.8 [SD 3.6] vs 37.1 [SD 2.4]; I: 14.9 [SD 3.5] vs 43.9 [SD 2.4]; 
p=0.01). 
In the other non-randomised controlled trial [18] the mean difference was cal-
culated to be 22.0 points in the WORC assessment in the intervention group, 
preoperatively versus last follow-up (C: 58.0 [SD 5.0] vs 66.0 [SD 5.0]; I: 54.0 
[SD 8.0] vs 84.0 [SD 4.0]; p=0.0412). 
Overall, across the studies and the different scores, partly statistically signif-
icant improvements in physical functioning in the intervention groups have 
been reported. 
 
Health-related quality of life 
D0012 – What is the effect of human dermal allograft  
on generic health-related quality of life? 
Health-related quality of life (HR-QoL) was assessed by three scores across 
two comparative studies [17, 18]. 
A non-randomised controlled trial [18], reported outcomes for SF-12 and 
WORC. Total SF-12 score mean difference was calculated to be 1.4 points 
higher in the intervention group regarding the mental component and of 5.7 
points higher in the intervention group regarding the physical component as 
measured preoperatively and at last follow-up. The total WORC mean differ- 
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ence was calculated to be 22.0 points higher compared to the control group, 
measured preoperatively and then at last follow-up (C: 58.0 [SD 5.0] vs 66.0 
[SD 5.0]; I: 54.0 [SD 8.0] vs 84.0 [SD 4.0]; p=0.0412). 
The other non-randomised controlled trial [17] reported total OSS including 
a sub-scale for HR-QoL. The patients were calculated to have a mean differ-
ence of 9.7 points higher in the intervention group (C: 17.8 [SD 3.6] vs 37.1 
[SD 2.4]; I: 14.9 [SD 3.5] vs 43.9 [SD 2.4]; p=0.01). 
Overall, the reported total scores for HR-QoL in the two non-randomised con-
trolled studies indicate an improvement in the intervention groups compared 
to the control groups, however, the difference was only statistically significant 
for the WORC score. 
D0013 – What is the effect of human dermal allograft  
on disease-specific quality of life? 
No evidence was found to answer this research question. 
 
Patient satisfaction 
D0017 – Was the use of human dermal allograft worthwhile? 
The randomised controlled trial provided patient satisfaction scores using the 
UCLA tool [35]. A non-statistically significant difference was found between 
groups, where the UCLA score increased from 15.9 to 28.3 (SD 3.0) in the 
control group and from 13.3 to 28.2 (SD 2.1) in the intervention group. In 
the UCLA tool, the patient satisfaction sub-score, a higher score represents 
better patient satisfaction. 
 
Minimal clinically important differences 
Published evidence has reported that the minimal clinically important dif-
ferences (MCID) for the following shoulder procedure outcomes are: ASES 
(13.6 ± 2.3), VAS (1.6 ± 0.3), Constant score (5.7 ± 1.9), WORC (245.26) and 
UCLA (8.7 ± 0.6) [36, 37]. 
Findings in this assessment are compared below to the published MCIDs. 
ASES has been reported in the randomised controlled trial and in one non-
randomised controlled trial with respective mean differences of 1.6 [35] and 
12.8 [18], meaning the difference is not clinically significant. VAS has also 
been reported in one non-randomised controlled trial with a difference of 2.7 
[18], meaning the difference is clinically significant. The Constant shoulder 
assessment was reported in the randomised controlled trial and in one non-
randomised controlled trial with respective mean differences of 11.4 [35] and 
15.0 [17], meaning differences can be considered clinically significant in both 
studies. WORC has been reported in one non-randomised controlled trial 
with a difference of 22.0 [18], showing the difference is not clinically signifi-
cant. Finally, UCLA was only reported in the randomised controlled trial 
with a mean difference of 2.5, meaning the difference is not clinically signif-
icant. Thus, MDIC may be indicated in VAS and Constant shoulder as-
sessment. 
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6 Safety 
6.1 Outcomes 
The following outcomes were defined as critical to derive  
a recommendation: 
 Procedure-related mortality 
 Failure rate/re-tears 
 Complications 
 Adverse events 
Procedure-related mortality was defined as deaths occurring within 24 months 
post-operatively or related to a complication incurred in the surgery. 
Failure/re-tears were reported when a shoulder failed to maintain adequate 
tissue to function as expected, or a re-tear was acknowledged on US or MRI. 
Complications were not defined in the studies. 
Adverse events were all events reported up to final follow up. 
In addition to the critical outcomes, one additional outcome was considered 
important but not crucial to the decision: 
 Re-operation/additional surgery 
Re-operation/additional surgery were not defined in the studies, but must be 
when another procedure to repair the rotator cuff was needed. 
 
 
6.2 Included Studies 
To evaluate the safety of human dermal allograft in rotator cuff repair surgery, 
we considered randomised controlled trials, prospective non-randomised con-
trolled trials and single arm studies.  
The same randomised controlled trial and two non-randomised controlled 
trials used for efficacy were used for safety, as well as, seven single arm stud-
ies which met the pre-defined inclusion criteria, including a total of 277 pa-
tients [17-20, 34, 35, 38-41]. The comparative trials are described in section 
5.2 and the seven single arm studies are described below. 
The seven single arm studies were all case series on patients, conducted in 
the USA, Switzerland, Italy, and Greece [19, 20, 34, 38-41]. One study [19] was 
supported by grants from Arthrex, and the others did not report any industry 
funding. 
In total, the case series included 174 patients with irreparable rotator cuff tear. 
All patients received rotator cuff tear repair with human dermal allograft. 
One study conducted in Switzerland treated three groups of patients with 
different commercial patches, only data on the patients receiving GraftJack-
et was extracted [39]. 
entscheidende 
Endpunkte für 
Sicherheit: ... 
... eingriffsbezogene 
Mortalität 
... Fehlerquote 
... Komplikationen 
... Nebenwirkungen 
weiterer (nicht-
entscheidungsrelevanter) 
Endpunkt 
Endpunkt nicht als 
solche in den Studien 
definiert 
kontrollierte und 
einarmige Studien  
für Sicherheit 
1 RCT, 2 N-RCTs &  
7 ein-armige Studien mit 
277 PatientInnen 
7 einarmige Studien aus 
Europa oder den USA,  
1 Studie gesponsert 
durch Arthrex 
mit insgesamt  
174 PatientInnen 
Human dermal allograft for massive rotator cuff tears 
40 LBI-HTA | 2019 
Four studies used GraftJacket [20, 38, 39, 41], one used ArthroFLEX [19], 
and the remaining two used a non-identified human dermal matrix [34, 40]. 
Post-operative treatments included abduction pillow sling for 3-8 weeks, as-
sisted gentle stretching for 3-6 weeks, assisted range of motion at approxi-
mately 6 weeks, then strengthening and progression to full activities at ap-
proximately 12 weeks. 
Mean patient age ranged from 48.0 years to 66.4 years across studies. In these 
studies, the participants were majority male, with the proportion of female pa-
tients ranging from 0.0 to 50.0% across studies. Mean follow up times ranged 
across studies from 12 to 36 months (range, 29-40). 
Study characteristics and results of included studies are displayed in Table 
A-1 and Table A-2 and in the evidence profile in Table A-8. 
 
 
6.3 Results 
Mortality 
D0001 – What is the expected beneficial effect of human  
dermal allograft on mortality? 
D0003 – What is the effect of human dermal allograft on the mortality 
due to causes other than irreparable rotator cuff tears? 
No study reported any procedure-related deaths, resulting in a combined 
procedure-related mortality rate of 0.0% (0/277).  
 
Patient safety 
C0008 – How safe is human dermal allograft in comparison  
to the comparator(s)? 
At a mean follow up of 24 months the randomised controlled trial [35] report-
ed failure rates were 45.0% (9/20) in the control group versus 13.6% (3/22) 
in the intervention group, these were not related to the allograft but related 
to further injuries of the shoulder. Reported failure rates in a non-random-
ised controlled trial [18] were 27.0% (4/15) in the control group versus 10.0% 
(2/20) in the intervention group at mean follow up of 24.9 months. The fail-
ure rate across the seven case series was 19.0% (24/126) with follow up times 
ranging from 12 to 77 months [19, 20, 34, 38-41]. 
No reoperation or additional surgery was reported in the randomised con-
trolled trial [35]. Reported reoperation rates in a non-randomised controlled 
trial [18] were 26.0% (3/15) in the control group versus 10.0% (2/20) in the 
intervention group at mean follow up of 24.9 months. The total reoperation 
rate across five case series was 18.0% (14/78) with follow up times ranging 
from 12 to 39 months [19, 38-41]. 
Six included studies reported complications, including a total of 192 patients 
and mean follow-up times ranging from 12 to 36 months [18, 20, 34, 35, 38, 
40]. Within these, only one study reported a complication. It was a non-ran-
domised controlled trial [18] which reported one patient had a complication 
after the procedure. This patient suffered a superficial skin infection one week 
post-operatively which was resolved after treatment with antibiotics. In the 
remaining four studies complications were not reported. 
4 einarmige Studien  
mit GraftJacket,  
1 mit ArthroFLEX,  
2 mit undefinierter 
Matrix, 
Rehabilitations-
programm in allen 7 
 
Ø Alter: 48,0-66,4 Jahre, 
0,0-50,0 % Frauen,  
Ø Nachbeobachtungszeit 
12-36 Monate 
 
Extraktionstabellen  
im Anhang 
keine eingriffs-
bezogenen Todesfälle 
1 RCT: Fehlerquoten 
45,0 vs. 13,6 %, 
1 N-RCT: 27,0 vs. 10,0 %, 
7 einarmige Studien: 
19,0 % 
1 N-RCT: Re-Operations-
rate 26,0 vs. 10,0 %, 
5 einarmige Studien: 
18,0 % 
1 N-RCT:  
1 Komplikation – 
Hautirritation, 
behandelt mit 
Antibiotika 
Safety 
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Five studies reported adverse events [19, 20, 35, 38, 40]. Three case series re-
ported none occurred and two studies [19, 35], the randomized controlled 
trial and one case series, reported 22 adverse events in total, resulting in a 
combined adverse event rate of 19.3% (22/114). The randomised controlled 
trial [35] had 14 adverse events in the control group (9 re-tears, 2 cellulitis, 1 
shoulder bursitis, 1 fibrosis, 1 bicep tendon rupture) (14/20 [70%]) and four 
adverse events in the intervention group (3 re-tears, 1 bursitis) (4/22 [18%]). 
The case series [19] reported four out of nine patients (4/9 [44.4%]) suffered 
from subsequent shoulder injuries. None of these four subsequent injuries 
were attributed to the presence of the human dermal allograft. The remain-
ing five studies did not report adverse events. 
Severe adverse events were not reported in any of the comparative studies. 
Two case series [38, 40], with mean follow up times ranging from 12 to 15 
months, did report severe adverse events. They both reported that none oc-
curred, resulting in a combined severe adverse event rate of 0.0% (0/22). 
C0002 – Are the harms related to dosage or frequency  
of applying human dermal allograft? 
Not applicable. 
C0004 – How does the frequency or severity of harms change  
over time or in different settings? 
No evidence was identified to answer this question. 
C0005 – What are the susceptible patient groups that are more  
likely to be harmed through the use of human dermal allograft? 
No evidence was identified to answer this question. 
C0007 – Are human dermal allograft and comparator(s) associated  
with user-dependent harms? 
No evidence was identified to answer this question. 
 
Investments and tools required 
B0010 – What kind of data/records and/or registry is needed  
to monitor the use of human dermal allograft and the comparator? 
International, prospective registry data would better inform the long-term 
safety of human dermal allograft. 
 
Nebenwirkungen  
nicht eingriffsbedingt: 
1 RCT: 70,0 vs. 18,0 % 
1 einarmige Studie: 
44,4 % mit folgenden 
Schulterverletzungen 
2 einarmige Studien: 
keine schwerwiegenden 
Nebenwirkungen 
keine Relevanz 
keine Evidenz 
keine Evidenz 
keine Evidenz 
internationale, 
prospektive  
Registerdaten 
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7 Quality of evidence 
Risk of bias in the randomised controlled trial was appraised using ‘The Coch-
rane Collaboration’s Tool for Assessing Risk of Bias in Randomised Trials’ 
[9] and is presented in Table A-4 (see Appendix). The randomised controlled 
trial appraised was at low risk of bias. Limited risks of bias were due to pa-
tient blinding not being explicitly described, and serious adverse events not 
being reported. 
Risk of bias in the non-randomised controlled trials was appraised using ‘The 
Risk Of Bias In Non-randomized Studies – of Interventions (ROBINS-I) as-
sessment tool‘ [10], as presented in Table A-5 (see Appendix). The studies 
were at serious risk of bias due to a lack of appropriate methods to control for 
confounding, as well as the risk of time-varying confounding in one study. 
Risk of bias in the single arm studies was appraised using the Institute of 
Health Economics (IHE) appraisal tool for case series studies [11], as pre-
sented in Table A-6 (see Appendix). The single arm studies were at low to 
high risk of bias. The main reasons for increasing the risk of bias were due 
outcome assessors not being blinded to intervention received (6 studies), un-
certainty if patients entered the study at same point in the disease (5 studies), 
the study being conducted retrospectively (2 studies), follow up not long 
enough (4 studies), and no reporting of adverse events (4 studies). 
The strength of evidence was rated according to GRADE (Grading of Rec-
ommendations Assessment, Development and Evaluation) Schema [12] for 
each endpoint individually. Each study was rated by two independent re-
searchers. In case of disagreement, a third researcher was involved to solve 
the difference. A more detailed list of criteria applied can be found in the re-
commendations of the GRADE Working Group [12]. 
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close  
to that of the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate: the 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in the summary of findings table below and in the evidence profile 
in Appendix Table A-7 & Table A-8. Patient satisfaction scores were not seen 
as critical outcomes in this assessment, and thus were not included in the 
GRADE analysis. 
Overall, the quality of evidence for the effectiveness and safety of surgical 
repair with human dermal allograft in comparison to surgical repair without 
human dermal allograft is considered “moderate”.  
 
RoB bewertet mit 
Cochrane Collaborations 
Tool (RCTs):  
niedriges Biasrisiko 
RoB bewerted mit 
ROBINS-I (N-RCTs): 
schwerwiegendes 
Biasrisiko 
RoB bewerted mit  
IHE Checklist 
(einarmige Studien): 
niedriges bis hohes 
Biasrisiko 
Qualität der Evidenz 
nach GRADE 
GRADE Tabelle nächste 
Seite und Appendix 
moderate Evidenzstärke 
für Wirksamkeit und 
Sicherheit 
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Table 7-1: Summary of findings table of human dermal allograft 
Outcome 
Anticipated absolute effects 
Relative 
effect 
Number of 
participants  
(studies, reference) 
Quality Comments Risk with 
[comparison] 
Risk with 
[intervention] Difference 
EFFICACY 
Change in pain score  
Assessed with: UCLA score; scale from: 0 to 35; 
follow up: range 12 months to 38 months 
NR NR MD 2.5* 
points higher 
in I1 
Not 
estimable 
42 
1 randomised 
controlled trial [35] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in pain 
Change in pain score  
Assessed with: ASES; scale from: 0 to 100;  
follow up: mean 24 months 
NR NR MD 1.6* 
points higher 
in I2 
Not 
estimable 
42 
1 randomised 
controlled trial [35] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in pain 
Change in pain score  
Assessed with: CS assessment; scale from: 0 to 100; 
follow up: mean 24 months 
NR NR MD 11.4* 
points higher 
in I3 
Not 
estimable 
42 
1 randomised 
controlled trial [35] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in pain 
Change in pain score  
Assessed with: ASES; scale from: 0 to 100;  
follow up: mean 24 months 
NR NR MD 12.8* 
points higher 
in I2 
Not 
estimable 
35 
1 non-randomised 
controlled trial [18] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in pain 
Change in pain score 
Assessed with: CS assessment; scale from: 0 to 100; 
follow up: range 24 months to 120 months 
NR  MD 15.0* 
points higher 
in I3 
Not 
estimable 
26 
1 non-randomised 
controlled trial [17] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in pain 
Change in pain score 
Assessed with: VAS Scale; scale from: 0 to 10;  
follow up: mean 24.9 months 
NR NR MD 2.7* 
points lower 
in I 
Not 
estimable 
35 
1 non-randomised 
controlled trial [18] 
⨁⨁⨁◯ 
MODERATE 
Lower scores indicate improvement 
in pain, significant improvment  
for intervention group 
Change in pain score 
Assessed with: OSS; scale from: 0 to 60;  
follow up: range 24 months to 120 months 
NR NR MD 9.7* 
points higher 
in I4 
Not 
estimable 
26 
1 non-randomised 
controlled trial [17] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in pain 
Change in ROM 
Assessed with: UCLA; scale from: 0 to 35;  
follow up: mean 24 months 
NR NR MD 2.5* 
points higher 
in I1 
Not 
estimable 
42 
1 randomised 
controlled trial [35] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in range  
of motion 
                                                             
1 Total UCLA score used, not the sub-scores for pain or range of motion. 
2 Total ASES score is used, not sub-scores for pain, range of motion or physical function. 
3 Total Constant shoulder (CS) assessment is used, not sub-scores for pain, range of motion or physical function. 
4 Total OSS score used, not the sub-score for pain, health-related quality of life or physical function. 
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4
5 
Outcome 
Anticipated absolute effects 
Relative 
effect 
Number of 
participants  
(studies, reference) 
Quality Comments Risk with 
[comparison] 
Risk with 
[intervention] Difference 
Change in ROM score 
Assessed with: CS assessment; scale from: 0 to 100; 
follow up: mean 24 months 
NR NR MD 11.4* 
points higher 
in I3 
Not 
estimable 
42 
1 randomised 
controlled trial [35] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in range  
of motion 
Change in ROM score 
Assessed with: ASES; scale from: 0 to 100;  
follow up: mean 24 months 
NR NR MD 1.6* 
points higher 
in I2 
Not 
estimable 
42 
1 randomised 
controlled trial [35] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in range  
of motion 
Change in ROM score 
Assessed with: CS assessment; scale from: 0 to 100; 
follow up: range 24 months to 120 months 
NR NR MD 15.0* 
points higher 
in I3 
Not 
estimable 
26 
1 non-randomised 
controlled trial [17] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in range  
of motion 
Change in ROM score 
Assessed with: ASES; scale from: 0 to 100;  
follow up: mean 24.9 months 
NR NR MD 12.8* 
points higher 
in I2 
Not 
estimable 
35 
1 non-randomised 
controlled trial [18] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in range  
of motion 
Change in ROM score 
Assessed with: WORC; scale from: 0 to 100; 
follow up: mean 24.9 months 
NR NR MD 22.0* 
points higher 
in I5 
Not 
estimable 
35 
1 non-randomised 
controlled trial [18] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in range  
of motion 
Change in physical function 
Assessed with: ASES; scale from: 0 to 100;  
follow up: mean 24 months 
NR NR MD 1.6* 
points higher 
in I2 
Not 
estimable 
42 
1 randomised 
controlled trial [35] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in physical  
function 
Change in physical function 
Assessed with: CS assessment; scale from: 0 to 100; 
follow up: median 24 months 
NR NR MD 11.4* 
points higher 
in I3 
Not 
estimable 
42 
1 randomised 
controlled trial [35] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in physical  
function 
Change in physical function 
Assessed with: ASES; scale from: 0 to 100;  
follow up: mean 24.9 months 
NR NR MD 12.8* 
points higher 
in I2 
Not 
estimable 
35 
1 non-randomised 
controlled trial [18] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in physical  
function 
Change in physical function 
Assessed with: CS assessment; scale from: 0 to 100; 
follow up: range 24 months to 120 months 
NR NR MD 15.0* 
points higher 
in I3 
Not 
estimable 
26 
1 non-randomised 
controlled trial [17] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in physical  
function 
Change in physical function 
Assessed with: OSS; scale from: 0 to 100;  
follow up: range 24 months to 120 months 
NR NR MD 9.7* 
points higher 
in I4 
Not 
estimable 
26 
1 non-randomised 
controlled trial [17] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in physical  
function 
Change in health-related quality of life 
Assessed with: WORC; scale from: 0 to 100; 
follow up: mean 24.9 months 
NR NR MD 
22.0*points 
higher in I6 
Not 
estimable 
35 
1 non-randomised 
controlled trial [18] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in range  
of motion 
                                                             
5 Total WORC used, not sub-score for range of motion, health-related quality of life. 
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Outcome 
Anticipated absolute effects 
Relative 
effect 
Number of 
participants  
(studies, reference) 
Quality Comments Risk with 
[comparison] 
Risk with 
[intervention] Difference 
Change in health-related quality of life 
Assessed with: SF-12; scale from: 0 to 100;  
follow up: mean 24.9 months 
NR NR Physcial: MD 
5.7* points 
higher in I 
Mental: 1.4 
points higher 
in I 
Not 
estimable 
35 
1 non-randomised 
controlled trial [18] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in health-related 
quality of life 
Change in health-related quality of life 
Assessed with: OSS; scale from: 0 to 60;  
follow up: range 24 months to 120 months 
NR NR MD 9.7* 
points higher 
in I4 
Not 
estimable 
26 
1 non-randomised 
controlled trial [17] 
⨁⨁⨁◯ 
MODERATE 
Higher scores indicate 
improvement in health-related 
quality of life 
SAFETY 
Procedure-related mortality 
follow up: mean 24 months, range 12-38 
Overall deaths:  
C: 0/20 (0.0%), I: 0/22 (0.0%) 
RR: NR 42 
1 randomised 
controlled trial [35] 
⨁⨁⨁⨁ 
HIGH 
No procedure-related mortality 
Procedure-related mortality 
follow up: range 22-120 months 
Overall deaths: 0/61 (0.0%) RR: NR 61 
2 non-randomised 
controlled trials  
[17, 18] 
⨁⨁◯◯ 
LOW 
No procedure-related mortality 
Procedure-related mortality 
follow up: range 12-77 months 
Overall deaths: 0/174 (0.0%) RR: NR 174 
7 case series 
[19, 20, 34, 38-41] 
⨁◯◯◯ 
VERY LOW 
No procedure-related mortality 
Failure of repair procedure/re-tears  
follow up: mean 24 months, range 12-38 
Overall failures: 
C: 9/20 (45.0%), I: 3/22 (12.6%) 
RR: NR 42 
1 randomised 
controlled trial [35] 
⨁⨁⨁⨁ 
HIGH 
Failures include nine rotator cuff 
re-tears (C) and three (I), not 
attributed to the presence of graft 
Failure of repair procedure/re-tears 
follow up: range 22-120 months 
Overall failures: 10/61 (16.4%) RR: NA 61 
2 non-randomised 
controlled trials [17, 
18] 
⨁⨁◯◯ 
LOW 
In one trial, two patients needed 
revision surgery after six months, 
one had reverse should 
arthroplasty after one year 
Failure of repair procedure/re-tears 
follow up: range 12-77 months 
Overall failures: 24/174 (13.8%) RR: NA 174 
7 case series 
[19, 20, 34, 38-41] 
⨁◯◯◯ 
VERY LOW 
Patients experienced failures in all 
seven case series. Causes include 
falls, MVA, re-tears, and 
glenohumeral fusion. 
Complications 
follow up: mean 24 months, range 12-38 
Overall complications: 
C: 0/20 (0.0%), I: 0/22 (0.0%) 
RR: NR 42 
1 randomised 
controlled trial [35] 
⨁⨁⨁⨁ 
HIGH 
No device- or procedure-related 
complications occurred/reported 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
6 Total WORC used, not sub-score for range of motion, health-related quality of life. 
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7 
Outcome 
Anticipated absolute effects 
Relative 
effect 
Number of 
participants  
(studies, reference) 
Quality Comments Risk with 
[comparison] 
Risk with 
[intervention] Difference 
Complications 
follow up: mean 24.9 months, range 22-26 
Overall complications: 1/35 (2.8%) RR: NR 35 
1 non-randomised 
controlled trial [18] 
⨁⨁◯◯ 
LOW 
Procedure-related complication, 
patient had a superficial skin 
infection one week after surgery 
Complications 
follow up: range 12-77 months 
Overall complications: 0/137 (0.0%) RR: NR 137 
4 case series 
[20, 34, 38, 40] 
⨁◯◯◯ 
VERY LOW 
No device- or procedure-related 
complications occurred/reported 
Adverse events 
follow up: mean 24 months, range 12-77 
Overall adverse events: 18/42 (42.8%) 
C: 14/20 (70.0%) , I: 4/22 (18.0%) 
RR: NR 42 
1 randomised 
controlled trial [35] 
⨁⨁⨁⨁ 
HIGH 
Control group = 14 AEs, including 
9 re-tears, 2 cellulitis, 1 shoulder 
bursitis, 1 post-traumatic fibrosis 
and 1 biceps tendon rupture. 
Intervention group = 4 AEs, 
including 3 re-tears and 1 bursitis. 
None were allograft-related. 
Adverse events 
follow up: range 12 40 months 
Overall adverse events: 4/55 (7.3%) RR: NR 55 
4 case series 
[19, 20, 38, 40] 
⨁◯◯◯ 
VERY LOW 
Four subsequent shoulder injuries 
(not attributed to the human 
dermal allograft). 
Abbreviations: AEs = adverse events; C = control group; I = intervention group; MVA = motor vehicle accidents; NA = not applicable; NR = not reported;  
ROM = Range of Motion; RR = relative risk.  
*Self-calculated. 
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
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8 Discussion 
Patients with rotator cuff tear experience debilitating shoulder pain, reduced 
shoulder function, and compromised joint mechanics [32]. Rotator cuff tear 
can usually be repaired with surgery. An irreparable rotator cuff tear is de-
fined as large (>3cm) or massive (>5cm), involving two or more tendons, and 
one which has undergone primary surgery without success [18, 25]. 
Several surgical techniques have been proposed, yet irreparable rotator cuff 
tear procedures are complicated by structural failure and other poor out-
comes. Various xenografts and synthetic allografts have also been proposed, 
to little success [2]. 
In patients under 65 years who do not have glenohumeral arthritis SCR using 
human dermal allograft for augmentation is the most common form of repair 
[2]. This form of repair was first reported in a case series in 2007. The study 
showed good clinical outcomes at short follow up [42]. There has since been 
growing interest in the human dermal allograft for rotator cuff tear repair. 
The aim of this systematic review was to evaluate the safety and effectiveness of 
rotator cuff tear repair surgery augmented with human dermal allograft in com-
parison to rotator cuff tear repair surgery without human dermal allograft. 
 
Available evidence 
Three studies, two non-randomised and one randomised, thus one being in-
dustry sponsored, were used to ascertain the efficacy of human dermal allo-
graft [17, 18, 35]. They assessed patients preoperatively and at last follow-up 
using seven scores which cover a range of patient specific factors. 
ASES, VAS, Constant shoulder assessment, WORC, and UCLA are used to 
assess all the critical outcomes: changes in pain, range of motion, physical 
function, and health-related quality of life. In the included studies, signifi-
cant clinically important differences have been found in VAS and Constant 
shoulder assessment. Although, small patient study sizes make this not me-
aningful. 
The three studies showed a slight improvement in pain, range of motion, 
physical functioning and health-related quality of life in the intervention 
groups across the different scores. However, this improvements were only 
partly statistically significant. Health-related quality of life was reported by 
the two non-randomised controlled trials as improved in the human dermal 
allograft groups, but as the studies are non-randomised these results should 
be viewed with caution. 
The safety evidence is made up of the same randomised controlled trial, two 
non-randomised controlled trials and additional seven case series [17-20, 34, 
35, 38-41]. 
All trials found human dermal allograft comparatively safe, with very few 
complications reported. The most commonly reported safety outcome was 
failure/re-tear. The randomised controlled trial reported failures rates were 
45.0% (9/20) in the control group versus 13.6% (3/22) in the intervention 
group, at mean 24 months follow-up. Failure rates in a non-randomised con-
trolled trial were slightly lower, 27.0% (4/15) in the control group versus 
10.0% (2/20) in the intervention group, at mean follow up of 24.9 months. 
No procedure-related deaths were reported in any study. 
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Out of the five studies that reported adverse events, three reported none had 
occurred and two reported a total of 22, giving a combined adverse event rate 
of 19.3% (22/114). 
Overall, the strength of evidence for the clinical effectiveness and safety of ro-
tator cuff tear repair surgery augmented with human dermal allograft in com-
parison to rotator cuff tear repair surgery without human dermal allograft was 
determined as “moderate”. The strength of evidence of the identified studies 
was mainly downgraded due to risk of time-varying confounding. 
 
Interpretation of study results 
There are several weaknesses in the evidence base around human dermal 
allograft. 
There are two products on the market fitting the definition of human dermal 
allograft for rotator cuff tear. GraftJacket which is produced by Wright Med-
ical Technology Inc. and Arthrex produced by Arthroflex Inc., both are com-
panies based in the United States. Table 3-1 outlines the features of these 
two products. As they are not the same product, there could be slight differ-
ences between the interventions assessed which might influence the results. 
The studies identified for assessing the intervention had low patient numbers 
and short follow-up periods, which can diminish the strength of the evidence. 
Efficacy was assessed with one randomised controlled trial, and two non-ran-
domised controlled trials with sample sizes ranging from 26 to 42 patients. 
The low patient numbers and relatively short follow-up periods can prevent 
true efficacy outcomes from being identified. 
The efficacy outcomes also relied on patient reported measures which leads 
to a level of subjectivity, which was taken into account in the RoB assessment. 
Some of these studies suffered from confusion in the reporting of outcomes 
in the published article. For example, inconsistencies were found in scores 
reported in the tables to the text. 
The efficacy outcomes were measured with various different scores within 
and across studies. Only overall scores and not specific sub-scores were re-
ported meaning that the interpretation of the effect of the intervention on a 
specific outcome was more difficult. However, it was calculated that in the 
included studies, significant clinically important differences may be indicat-
ed in VAS and Constant shoulder assessment. This would have more power 
if the studies included more patients. 
There were also issues around confounding adjustment, where study authors 
had not used an appropriate method for controlling for confounding in the 
non-randomised studies. 
The reported safety evidence had low strength of evidence due to the study 
designs. Safety was assessed the same two non-randomised controlled trials, 
and one randomised controlled trial and additional seven single arm studies. 
The low patient numbers and short follow-up periods of the studies can be 
particularly problematic for identifying possible serious/rare adverse events. 
Despite weaknesses of the evidence, human dermal allograft seem to have 
equal or better safety to the comparator intervention. 
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Additional discussion on available evidence 
As the target population of the present report are patients with irreparable 
rotator cuff tears, the included studies for effectiveness do not present the 
most suitable comparators. In fact, for rotator cuff reconstruction surgeries 
with human dermal allograft, reconstruction surgeries without human der-
mal allograft, like tendon transfer or inverse arthroplasty, would have been 
the appropriate comparators. 
It was very rarely reported whether patients received additional medication 
after the surgical procedure or not. Furthermore, information on longer term 
medication use and symptom control was lacking. For example, the consump-
tion of pain relievers during the trial and up to final follow-up could have im-
pacted the assessment of outcomes such as pain and health-related quality of 
life. Reporting of this measure in the trials would improve understanding of 
the effect of the intervention. 
All included studies reported on post-operative rehabilitation programmes. 
However, the effects of these post-operative therapies on the overall efficacy 
and safety outcomes were not considered. Thus, there is a possible confound-
ing effect on the reported findings. 
In general, the population of the included studies were patients who are still 
of working age. This could indicate additional costs to society as massive ro-
tator cuff tear impacts an individual’s quality of life and therefore their abil-
ity to work. The patients are likely to experience extended leave from work 
and less productivity at work. They may require more sick leave and need to 
change to another work role (requiring retraining), or even need to enter in-
to retirement early. 
For a summary of the applicability of the included studies to the population 
likely to receive the intervention, see the Applicability table in the Appendix. 
 
Upcoming evidence 
Four randomised controlled trials and one non-randomised controlled trial are 
reportedly underway with completion dates before mid-2020. They are being 
conducted in Canada, the United States and Europe. All studies compare ro-
tator cuff repair using augmentation with a human dermal allograft with the 
same procedure without any graft. They are reported to include a total of 244 
patients, with follow-up of 12 months in one trial, where the other trials did 
not report follow-up. Once these have been completed and published results 
are available, the evidence on human dermal allograft is expected be greatly 
strengthened. 
 
Limitations to our study 
We excluded retrospective studies for assessment of efficacy – even controlled 
studies with a retrospective control group – because the sources of error due 
to confounding and bias are more common in retrospective studies than in 
prospective ones. 
The manufacturers did not respond to communication around the publica-
tion, so further information could not be obtained. In addition, it is possible 
that not all manufacturers were identified. 
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Moreover, different terminologies for the surgery with human dermal allo-
graft in patients with irreparable rotator cuff tears, ranging from rotator cuff 
repair/reconstruction and replacement to superior capsular reconstruction 
may have precluded identification of all appropriate studies. In the present 
report, the repair of irreparable rotator cuff tears with human dermal allograft 
was used as an overall term for the reconstruction of irreparable rotator cuff 
tears. 
In all included studies efficacy outcomes were measured with various differ-
ent scores within and across the studies. Therefore and because of the differ-
ent study designs, for most of the scores only one study was available for per-
forming the GRADE analysis. This could have had an impact on the explan-
atory power of the strength of evidence resulted from the analysis. 
Overall, the results of this review should be interpreted in light of the limita-
tions. We only included one randomised study and it was industry funded. 
We did include seven single arm studies with no limits to follow up or sam-
ple size. This may have invited low quality studies into the assessment. 
 
Conclusion 
In the absence of objective, randomised studies it is difficult to ascertain the 
relative risks and benefit of rotator cuff tear repair with human dermal allo-
graft in comparison to rotator cuff tear repair alone. However, from the lim-
ited evidence, of moderate quality, it appears rotator cuff tear repair with 
human dermal allograft might be more effective, and equally safe or safer as 
its comparator. 
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and  
the according choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
X The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence indicates, that the assessed technology reconstruction 
of the rotator cuff tear with human dermal allograft (when restricted to cases 
where there is a high likelihood of poor healing after rotator cuff tear repair) 
is more effective and equally safe or safer compared with the comparator, sur-
gical rotator cuff tear repair without use of human dermal allograft. 
However, due to the limited strength of evidence, these results should be in-
terpreted with caution. As a result, the reconstruction of irreparable rotator 
cuff tears with human dermal allograft is currently not recommended for the 
inclusion in the Austrian hospital benefit catalogue. 
There are four randomised controlled trials which all expect to be completed 
by mid-2020, the results from these should add value to the evidence base on 
human dermal allograft (see List of ongoing randomised controlled trials in 
the Appendix). 
The re-evaluation is recommended in 2021, when some of these trials have 
published results. 
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Appendix 
Evidence tables of individual studies included 
for clinical effectiveness and safety 
Table A-1: Human dermal allograft for irreparable rotator cuff tears: Results from randomised controlled trials 
Author, year [Reference] Barber, 2012 [35] 
Country USA/Canada 
Sponsor Wright Medical Technologies 
Intervention/Product GraftJacket: 
3-dimensional human dermal tissue scaffold from native collagen structure 
Comparator Rotator cuff tear repair without augmentation 
Study design Prospective, multicentre, randomised controlled trial 
Number of pts 42: 
C: 20 
I: 22 
Inclusion criteria Large (3-5cm), 2-tendon rotator cuff tear that could be repaired arthroscopically, 
age 18-75 years, 
good preoperative movement of the non-operative arm (>90°), 
ability to perform post-operative exercises, 
ability to conduct patient reported outcomes 
Exclusion criteria Irreparable massive rotator cuff tear (>5 cm), 
subscapularis tendon disruptions, 
revision surgery, 
inflammatory or autoimmune diseases, 
evidence of active infection, 
cancer or highly communicable diseases, 
smokers, 
pts. not expected to be able to participate in the protocol-required  
post-operative follow up examination. 
Mean age of patients (yrs, range) C: 56 (34-72) 
I: 56 (43-69) 
Female sex, n (%) C: 7 (35*) 
I: 4 (18.18*) 
Post-operative treatment(s) Use of abduction sling for 4-6 weeks, allowing daily pendulum motion exercises, 
start of supervised physical therapy at 4 weeks, with strengthening allowed 
starting at 12 weeks 
Follow up (months) 24 (range, 12-38) 
Loss to follow up, n (%) Not reported 
Primary endpoint(s) Presence of residual tendon defects on MRI at 1 year 
Outcomes 
Efficacy 
Pain, scores 
 ULCA (pre-operatively vs  
last follow up)1  
C: 15.9 vs 28.3 (SD 3.0) 
I: 13.3 vs 28.2 (SD 2.1) 
(P=0.43) 
 ASES (pre-operatively vs  
last follow up)2  
C: 46.0 vs 94.8 (SD 14.2) 
I: 48.5 vs 98.9 (SD 4.2) 
(P=0.035) 
 CS (pre-operatively vs  
last follow up)3  
C: 45.8 vs 85.3 (SD 11.0) 
I: 41.0 vs 91.9 (SD 9.2) 
(P=0.008) 
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Author, year [Reference] Barber, 2012 [35] 
 OSS Not reported 
 DASH Not reported 
 SPADI Not reported 
 VAS Not reported 
ROM, scores 
 ULCA (pre-operatively vs last 
follow up)1 
C: 15.9 vs 28.3 (SD 3.0) 
I: 13.3 vs 28.2 (SD 2.1) 
(P=0.43) 
 WORC Not reported 
 CS (pre-operatively vs  
last follow up)3  
C: 45.8 vs 85.3 (SD 11.0) 
I: 41.0 vs 91.9 (SD 9.2) 
(P=0.008) 
 ASES (pre-operatively vs last 
follow up)2  
C: 46.0 vs 94.8 (SD 14.2) 
I: 48.5 vs 98.9 (SD 4.2) 
(P=0.035) 
 ROM Not reported 
Physical function, scores 
 SSV Not reported 
 WORC Not reported 
 DASH Not reported 
 SPADI Not reported 
 ASES (pre-operatively vs  
last follow up)2  
C: 46.0 vs 94.8 (SD 14.2) 
I: 48.5 vs 98.9 (SD 4.2) 
(P=0.035) 
 CS (pre-operatively vs last 
follow up)3  
C: 45.8 vs 85.3 (SD 11.0) 
I: 41.0 vs 91.9 (SD 9.2) 
(P=0.008) 
 OSS Not reported 
Health-related quality of life, scores 
 OSS Not reported 
 SF-12 Not reported 
 WORC Not reported 
Patient satisfaction, scores 
 ULCA (pre-operatively vs  
last follow up)1  
C: 15.9 vs 28.3 (SD 3.0) 
I: 13.3 vs 28.2 (SD 2.1) 
(P=0.43) 
 SSV Not reported 
 MRI scan of intact cuffs, n (%) C: 17 (85) 
I: 6 (407) 
(P<0.01) 
Safety 
Procedure-related mortality 0/42 (0.0) 
Failure of repair procedure,  
re-tear-rate (%)  
C: 9/20 (45.0*) 
I: 3/22 (13.6*) 
Additional surgery,  
re-operation-rate (%) 
Not reported 
Complications 
 Procedure-related Not reported 
 Device-related 0/22 (0.0) 
                                                             
7 In the intervention group only 15 out of 22 pts. underwent MRI. 
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Author, year [Reference] Barber, 2012 [35] 
Adverse events  C: 148/20 
I: 49/22 
Severe adverse events Not reported 
Abbreviations: ASES = American Shoulder and Elbow Surgeons; C = control group; CS = Constant shoulder assessment; 
DASH = Disabilities of the arm, shoulder, and hand; I = intervention group; MRI = magnetic resonance imaging;  
OSS = Oxford Shoulder Score; ROM = Range Of Motion; SD = standard deviation; SPADI = Shoulder Pain and 
Disability Index; SSV = Subjective shoulder value; UCLA = University of California, Los Angeles; USA = United States  
of America; VAS = Visual analogue scale; WORC = Western Ontario Rotator Cuff Index. 
* Self-calculated. 
 
Table A-2: Human dermal allograft for irreparable rotator cuff tears: Results from non-randomised controlled studies 
Author, year [Reference] Gilot, 2015 [18] Pandey, 2017 [17] 
Country USA UK 
Sponsor Not reported None 
Intervention/Product ArthroFLEX: 
Acellular dermal extracellular matrix 
(ECM) of collagen, elastin and growth 
factors providing supplemental support 
and covering for soft tisue repair 
GraftJacket: 
Human dermal cell-free tissue with  
an intact matrix to retain collagen, 
proteoglycans and elastin 
Comparator Rotator cuff tear repair without 
augmentation with ECM graft 
Partial repair without GraftJacket graft 
Study design Non-randomised, prospective, blinded, 
single-centre, controlled trial 
Prospective non-randomised controlled 
trial 
Number of pts 35 
C: 15 
I: 20 
26: 
C: 13 
I: 13 
Inclusion criteria Patient with large (3.0-5.0 cm) or masssive 
rotator cuff tear (>5 cm) as seen on MRI, 
scheduled to undergo primary rotator cuff 
tear repair, aged 18-85 years, and willing 
to provide scores for the study 
Massive rotator cuff tear (>5 cm) not 
amenable to complete repair 
Exclusion criteria Known allergy to ECM material, addiction 
to illegal drugs and involved in a treatment 
program, infection, pregnant or breast 
feeeding, history of autoimmune disease, 
and beliefs prohibiting the use of grafts  
Previous shoulder surgeries with 
established glenohumeral osteoarthritis, 
cuff tears, which could be completely 
repaired 
Mean age of patients  
(yrs, SD) 
C: 62.0 (SD4.6) 
I: 58.9 (SD6.2) 
(P=0.683) 
C: 59 (range, 45-67) 
I: 57 (range, 45-68) 
Female sex, n (%) C: 8.0 (53.0) 
I: 12.0 (40.0) 
(p=0.514) 
C: 4 (30.77*) 
I: 4 (30.77*) 
Post-operative treatment(s) First 6 weeks: sling immobilisation, 
additional 6 weeks passive motion, 
additional 6 weeks active motion, after  
18 weeks strengthening exercises 
Use of polysling for 6 weeks  
to immobilise the shoulder, 
initiation of strenghtening exercises  
at 3 months 
Follow up (months) 24.9 (22-26) Min. 24 (2-5 years) 
Loss to follow up, n (%) 0/35 (0.0) 0/26 (0.0) 
Primary endpoint(s) Precence or abscene of a re-tear  
as noted on MRI or US examination 
Not reported 
                                                             
8 The 14 AEs include the 9 cases of re-tears and additionally, cellulitis, shoulder bursitis, post-traumatic fibrosis 
and a biceps tendon rupture. 
9 The 4 AEs include the 3 cases of re-tears and an additional case of bursitis. 
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Author, year [Reference] Gilot, 2015 [18] Pandey, 2017 [17] 
Outcomes 
Efficacy 
Pain, scores 
 ULCA Not reported Not reported 
 ASES (pre-operatively vs 
last follow up)2 
C: 60.3 (SD 9.5) vs 72.6 (11.9) 
[improvement +9.9 (SD 24.7)] 
I: 63.8 (SD 13.8) vs 88.9 (SD 4.8) 
[improvement +29.9 (SD 18.6)] 
Significant better improvement  
for I at 96 week (P=0.024) 
Not reported 
 CS (pre-operatively vs 
last follow up3 
Not reported C: 43.1 (SD 3.9) vs 70.8 (SD 5.3) (P=0.01)  
I: 41.2 (SD 3.1) vs 83.9 (SD 6.0) (P=0.005)) 
Significant better improvement  
for I at 24 months (P<0.01) 
 OSS4 Not reported C: 17.8 (SD 3.6) vs 37.1 (SD 2.4) (P =0.009)  
I: 14.9 (SD 3.5) vs 43.9 (SD 2.4) (P =0.005)) 
Significant better improvements  
for I at 24 months (P=0.01) 
 DASH Not reported Not reported 
 SPADI Not reported Not reported 
 VAS (pre-operatively vs 
last follow up) 
C: 6.9 (SD 1.1) vs 4.1 (SD 1.1) 
[improvement + 2.1 (SD 2.0)] 
I: 6.8 (SD 1.6) vs 1.3 (SD 1.2) 
[improvement +5.9 (SD 1.1)] 
Significant better improvements  
for I (P=0.024) 
Not reported 
ROM, scores 
 ULCA Not reported Not reported 
 WORC (percentage  
pre-operatively vs last 
follow up)5 
C: 58.0 (SD 5.0) vs 66.0 (SD 5.0) 
[improvement +13.0 (SD 10.0)] 
I: 54.0 (SD 8.0) vs 84.0 (SD 4.0) 
[improvement +30.0* (SD 12.0)] 
Significant better improvement  
for I (P=0.0412) 
Not reported 
 CS (pre-operatively vs 
last follow up)3  
Not reported C: 43.1 (SD 3.9) vs 70.8 (SD 5.3) (P=0.01)  
I: 41.2 (SD 3.1) vs 83.9 (SD 6.0) (P=0.005)) 
Significant better improvement  
for I for 24 months (P<0.01) 
 ASES (pre-operatively vs 
last follow up)2 
C: 60.3 (SD 9.5) vs 72.6 (11.9) 
[improvement +9.9 (SD 24.7)] 
I: 63.8 (SD 13.8) vs 88.9 (SD 4.8) 
[improvement +29.9 (SD 18.6)] 
Significant better improvement  
for I at 96 week (P=0.024) 
Not reported 
 ROM Not reported Not reported 
Physical function, scores 
 SSV Not reported Not reported 
 WORC Not reported Not reported 
 DASH Not reported Not reported 
 SPADI Not reported Not reported 
 ASES (pre-operatively vs 
last follow up)2  
C: 60.3 (SD 9.5) vs 72.6 (11.9) 
[improvement +9.9 (SD 24.7)] 
I: 63.8 (SD 13.8) vs 88.9 (SD 4.8) 
[improvement +29.9 (SD 18.6)] 
Significant better improvement  
for I at 96 week (P=0.024) 
Not reported 
Appendix 
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Author, year [Reference] Gilot, 2015 [18] Pandey, 2017 [17] 
 CS (pre-operatively vs 
last follow up)3 
Not reported C: 43.1 (SD 3.9) vs 70.8 (SD 5.3) (P=0.01)  
I: 41.2 (SD 3.1) vs 83.9 (SD 6.0) (P=0.005)) 
Significant better improvement  
for I at 24 months (P<0.01) 
 OSS (pre-operatively vs 
last follow up)4  
Not reported C: 17.8 (SD 3.6) vs 37.1 (SD 2.4) (P=0.009) 
I: 14.9 (SD 3.5)vs 43.9 (SD 2.4) (P=0.005) 
Significant better improvements  
for I at 24 months (P=0.01) 
Health-related quality of life, scores 
 OSS (pre-operatively vs 
last follow up)4  
Not reported C: 17.8 (SD 3.6) vs 37.1 (SD 2.4) (P =0.009) 
I: 14.9 (SD 3.5)vs 43.9 (SD 2.4) (P=0.005) 
Significant better improvements  
for I at 24 months (P=0.01) 
 SF-12 (pre-operatively vs 
last follow up) 
C: 43.1 (SD 8.2) vs. 42.9 (SD 10.8) 
difference 3.7 (SD 12.7) 
I: 42.2 (SD 12.1) vs. 64.1 (9.3) difference  
5.1 (SD 11.7) 
Not reported 
 WORC (Percantage  
pre-operatively vs  
last follow up)5  
C: 58.0 (SD 5.0) vs 66.0 (SD 5.0) 
[improvement +13.0 (SD 10.0)] 
I: 54.0 (SD 8.0) vs 84.0 (SD 4.0) 
[improvement +30.0* (SD 12.0)] 
Significant better improvement  
for I (P=0.0412) 
Not reported 
Patient satisfaction, scores 
 ULCA Not reported Not reported 
 SSV Not reported Not reported 
 MRI scan of intact cuffs,  
n (%) 
C: 11/15 (73.3*) 
I: 18/20 (90.0*) 
Not reported 
Safety 
Procedure-related mortality 0/35 (0.0) 0/26 (0.0) 
Failure of repair procedure, 
re-tear-rate (%)  
C: 4/15 (26.8) 
I: 2/20 (10) 
(p=0.0483) 
C: 0/13 (0.0) 
I: 4/13 (30.0) 
Additional surgery,  
re-operation-rate (%) 
C: 3/15 (26.0)10 
I: 2/20 (10.0) 
Not reported 
Complications 
 Procedure-related C: 0/15 (0.0) 
I: 1/20 (5.0)11 
Not reported 
 Device-related C: 0/15 (0.0) 
I: 0/15 (0.0) 
Not reported 
Adverse events  Not reported Not reported 
Severe adverse events Not reported Not reported 
Abbreviations: ASES = American Shoulder and Elbow Surgeons; C = control group; CS = Constant shoulder assessment; 
DASH = Disabilities of the arm, shoulder, and hand; ECM = extracellular matrix; I = intervention group; OSS = Oxford 
Shoulder Score; ROM = Range Of Motion; SD = standard deviation; SPADI = Shoulder Pain and Disability Index;  
SSV = Subjective shoulder value; UCLA = University of California, Los Angeles; UK = United Kingdom;  
USA = United States of America; VAS = Visual analogue scale; WORC = Western Ontario Rotator Cuff Index. 
* Self-calculated. 
 
                                                             
10 Of the 4 pts. with a re-tear, 2 pts. needed revision surgery after 6 months and 1 pt. required a reverse shoulder  
arthroplasty after 1 year. 
11 1 pt. Had a superficial skin infection 1 week after surgery. 
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Table A-3: Human dermal allograft for irreparable rotator cuff tears: Results from observational studies 
Author, year [Reference] Burkhead, 2007 [38] Rotini, 2011 [40] Gupta, 2012 [20] Varvitsiotis, 2015 [34] Leuzinger, 2016 [39] Hirahara, 2018 [19] Sharma, 2018 [41] 
Country USA Italy USA Greece Switzerland USA UK 
Sponsor Not reported Not reported Not reported None Not reported Arthrex None 
Intervention/Product GraftJacket AHDM: 
Acellular human 
dermal matrix 
GraftJacket Fascia lata allograft GraftJacket: human 
dermal cell-free tissue 
with an intact matrix 
to retain collagen, 
proteoglycans and 
elastin 
ArthroFLEX GraftJacket 
Study design Case series 
retrospective12 
Case series Case series Case series Case series Case series Case series 
retrospective13 
Number of pts 17 6 24 68 28 9 22 
Inclusion criteria Massive or failed 
rotator cuff tear 
involving two or 
more tendons 
Large/massive 
rotator cuff lesions 
with high risk of 
recurrence in 
healthy patients 
aged <55 years, 
lesions involving 
infraspinatus and 
supraspinatus 
tendons, tendon 
retraction ≤3 accord-
ing to Thomazeau, 
fatty degeneration 
≤3 according to 
Goutallier, possibility 
of surgery for tendon 
reduction,  
follow up >1 year 
Patients with  
massive irreparable 
rotator cuff tear  
(>5 cm), 
failure of a minimum 
6 months’ non-
operative 
management, 
inability to reduce 
residual cuff to 
anatomic footprint 
(after full mobilisation 
of tendon),  
ability to fully 
participate in post-
operative 
rehabilitation 
protocol 
Patients with 
massive rotator cuff 
tear symptomatic 
with nocturnal pain 
and decreased 
functioning, 
irreparable by simple 
suture, at least  
2 ruptured tendons, 
>5 in maximal 
diameter,  
proven by MRI,  
and confirmed at 
surgery 
Massive rotator cuff 
tear involving 2 or 
more tendons 
Patients with 
irreparable massive 
rotator cuff tear 
Rotator cuff tear 
with pain and where 
direct repair is not 
possible 
                                                             
12 Indicated by no reporting of inclusion/exclusion criteria. 
13 Indicated by change of procedure after study start . 
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Author, year [Reference] Burkhead, 2007 [38] Rotini, 2011 [40] Gupta, 2012 [20] Varvitsiotis, 2015 [34] Leuzinger, 2016 [39] Hirahara, 2018 [19] Sharma, 2018 [41] 
Exclusion criteria Irreparable tendon 
for stable repair, 
active infection 
Arthritic degeneration 
even mild according 
to Samilson, frozen 
shoulder, symptomatic 
acromioclavicular 
arthritis, inability to 
cope with an a  
post-operative 
rehabilitation regime, 
autoimmune 
connective disease 
tissue, pork and 
penicillin alleriges 
Glenohumeral 
arthritis/rotator cuff 
tear arthropathy 
>50% fatty 
infiltration of the 
supraspinatus 
muscle, 
prior RC repair, 
RC reducible to 
lateral footprint 
during arthroscopy 
Advanced 
glenohumeral 
arthritis 
Osteoarthritis, 
fatty degeneration 
>2 according to 
Goutallier 
Not reported Not reported 
Mean age of patients 
(yrs, range)  
56.9 48.0 (37-55) 63 (45-83) 64.9 (43-81) 66.4 (SD 7.9) 61.3 (47-78) 64.6 (39-87) 
Female sex, n (%) 5 (29.41*) 0 (0.0) 12 (50*) 30 (44.1*) 8 (28.6) 2 (25*) 4 (20*) 
Post-operative 
treatments (s) 
Immobilisation with 
an abduction pillow 
45° with no motion 
for 3 weeks, 
passive motion 
above the pillow for 
additional 3 weeks 
or conversion to an 
Ultra-Sling, 
active assisted range 
of motion initiated 
at 6 weeks, 
strengthening 
delayed until at least 
12 weeks 
Use of abduction 
pillow sling for  
30 days after surgery, 
following gentle 
rehabilitation with 
gradual 
strengthening 
exercises after  
3 months 
Pain free passive 
range of motion 
until week 8, 
progressive active 
assisted range of 
motion until week 12, 
progressive isometric 
strengthening 
exercises start  
week 12, 
progression to full 
activities of daily 
living start after  
4 months 
Use of standard 
abduction pillow for 
first 6 weeks with 
starting pendulum 
exercises after  
3 weeks, 
passive motion 
continued for  
6 additional weeks, 
strengthening 
started at 12 weeks, 
resistance exercises 
at 16 weeks, 
return to activity  
as tolerated at  
24 weeks 
Not reported Not reported Pendulum exercises 
and passive 
movement during 
first 3 weeks, 
gentle stretching 
and active assisted 
movements from 
week 3 to 6, 
full ROM together 
with proprioceptive 
stretching was 
permitted after  
6 weeks 
Follow up (months) Mean 15* 12 for all Mean 36  
(range, 29-40) 
12 for all, 
mean 43 (31-77) 
36 Mean 32.4  
(range, 25-39) 
24.5 and 18 for  
two groups14 
Loss to follow up, n (%) 0/17 (0.0) 1/6 (16.7) 0/24 (0.0) 0/68 (0.0) 3/92 (3.3*)15 1/9 (11.1) 2/22 (9.1) 
Primary endpoint(s) Not reporded Safety and efficacy 
of the membrane 
Not reported Not reported Not reported Not reported Not reported 
                                                             
14 Group 1 included 2 pts. Treated with a single interpositional GraftJacket repair. In group 2, 18 pts. were treated with a doubled GraftJacket. 
15 Loss- to follow-up due to non-specific foreign body reaction 2 weeks after the implantation. 
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Author, year [Reference] Burkhead, 2007 [38] Rotini, 2011 [40] Gupta, 2012 [20] Varvitsiotis, 2015 [34] Leuzinger, 2016 [39] Hirahara, 2018 [19] Sharma, 2018 [41] 
Outcomes 
Efficacy 
Pain, scores 
 ULCA (pre- vs  
post-operatively)1  
9.1 vs 26.1  
(P<0.001) 
Not reported Not reported Not reported Not reported Not reported Not reported 
 ASES (pre-operatively 
vs last follow up)2  
Not reported Not reported 66.6 vs 88.7 
(P<0.001) 
Not reported Not reported 41.8 (SD 12.7)vs 86.5 
(SD 12.7) (P<0.001) 
Not reported 
 CS (pre- vs  
post-operatively)3  
Not reported 64.0 (range, 55-75) vs 
88.0 (range, 77-95) 
Avegage increase of 
24 (range 20-30) 
Not reported 32.5 vs 88.7 t=6 months16: 
47.3 (SD 7.3) vs.  
81.4 (SD 11.4) 
(p=0.002) 
Not reported Not reported 
 OSS4 Not reported Not reported Not reported Not reported Not reported Not reported 22 (SD 4.5) vs 45.5 
(SD 2.5) at 17 months 
(P<0.001)17 
 DASH Not reported Not reported Not reported Not reported Not reported Not reported Not reported 
 SPADI Not reported Not reported Not reported Not reported Not reported Not reported Not reported 
 VAS Not reported Not reported Not reported Not reported Not reported 6.3 (SD 1.6) vs 0.4 
(SD 1.1) (P<0.001) 
Not reported 
ROM, scores 
 ULCA (pre- vs  
post-operatively)1 
9.1 vs 26.1  
(P<0.001) 
Not reported Not reported Not reported Not reported Not reported Not reported 
 WORC Not reported Not reported Not reported Not reported Not reported Not reported Not reported 
 CS (pre- vs  
post-operatively)3  
Not reported 64.0 (range, 55-75) vs 
88.0 (range, 77-95) 
Avegage increase of 
24 (range 20-30) 
Not reported 32.5 vs 88.7 t=6 months 
47.3 (SD 7.3) vs. 81.4 
(SD 11.4) 
(p=0.002) 
Not reported Not reported 
 ASES (pre-operatively 
vs last follow up) 2 
Not reported Not reported 66.6 vs 88.7 
(P<0.001) 
Not reported Not reported 41.8 (SD 12.7) vs 
86.5 (SD 12.7) 
(P<0.001) 
Not reported 
 ROM Not reported Not reported Not reported Not reported Not reported Not reported Not reported 
                                                             
16 Mean CS score for all pts. was only reported for the follow-up of 6 months. 
17 OSS scores were only extracted for group 2 (n=18). However, scores were only available of 13/18 pts (72.2%). 
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Author, year [Reference] Burkhead, 2007 [38] Rotini, 2011 [40] Gupta, 2012 [20] Varvitsiotis, 2015 [34] Leuzinger, 2016 [39] Hirahara, 2018 [19] Sharma, 2018 [41] 
Physical function, scores 
 SSV Not reported Not reported Not reported Not reported t= 6 months: 
4.3 (SD 0.8) vs.  
8.2 (SD 1.1) 
(p=0.002) 
t= 36 months: 
4.3 (SD 0.8) vs.  
9.1 (SD 1.2) 
(p=0.002) 
Not reported Not reported 
 WORC Not reported Not reported Not reported Not reported Not reported Not reported Not reported 
 DASH Not reported Not reported Not reported Not reported Not reported Not reported Not reported 
 SPADI Not reported Not reported Not reported Not reported Not reported Not reported Not reported 
 ASES (pre-operatively 
vs last follow up)2 
Not reported Not reported 66.6 vs 88.7 
(P<0.001) 
Not reported Not reported 41.8 (SD 12.7) vs 
86.5 (SD 12.7) 
(P<0.001) 
Not reported 
 CS (pre- vs  
post-operatively)3  
Not reported 64.0 (range, 55-75) vs 
88.0 (range, 77-95) 
Avegage increase of 
24 (range 20-30) 
Not reported 32.5 vs 88.7 t=6 months: 
47.3 (SD 7.3) vs.  
81.4 (SD 11.4) 
(p=0.002) 
Not reported Not reported 
 UCLA (pre- vs  
post-operatively)1  
9.1 vs 26.1 (P<0.001) Not reported Not reported Not reported Not reported Not reported Not reported 
 OSS4 Not reported Not reported Not reported Not reported Not reported Not reported 22 (SD 4.5) vs  
45.5 (SD 2.5) 
(P<0.001)17 
Health-related quality of life, scores 
 OSS4 Not reported Not reported Not reported Not reported Not reported Not reported 22 (SD 4.5) vs 45.5 
(SD 2.5) (P<0.001)17 
 SF-12 (pre-operatively 
vs last follow up) 
Not reported Not reported 48.8 vs 56.8 
(P=0.03) 
Not reported Not reported Not reported (Post-operative) 
Physical 47.4 (SD 9.19); 
Mental 56.6 (SD 5.48) 
 WORC Not reported Not reported Not reported Not reported Not reported Not reported Not reported 
Patient satisfaction, scores 
 ULCA (pre- vs  
post-operatively)1 
9.1 vs 26.1 (P<0.001) Not reported Not reported Not reported Not reported Not reported Not reported 
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Author, year [Reference] Burkhead, 2007 [38] Rotini, 2011 [40] Gupta, 2012 [20] Varvitsiotis, 2015 [34] Leuzinger, 2016 [39] Hirahara, 2018 [19] Sharma, 2018 [41] 
 SSV  Not reported Not reported Not reported t= 6 months: 
4.3 (SD 0.8) vs.  
8.2 (SD 1.1) 
(p=0.002) 
t= 36 months: 
4.3 (SD 0.8) vs.  
9.1 (SD 1.2) 
(p=0.002) 
Not reported Not reported 
 MRI scan of intact 
cuff, n (%) 
9/11 (81.8*) 3/5 (60*) 14/19 (74) 27/30 (90*)18 14/16 (87.5*) 7/8 (87.5) Not reported 
Safety 
Procedure-related 
mortality 
0/17 (0.0) 0/5 (0.0) 0/24 (0.0)/ 
Not reported 
0/68 (0.0) 0/89 (0.0) 0/8 (0.0) 0/22 (0.0) 
Failure of repair 
procedure, re-tear-rate 
(%)  
3/11 (27.3*) 
re-tears—no action 
(n=2), glenohumeral 
fusion (n=1) 
2/5 (40.0) 
re-tears – no action 
1/24 (4.2*)19 3/30 (10.0*) 12/28 (42.9*) 2/8 (12.5) 
caused by a 
fall/motor vehicle 
accident – no actions 
1/20 (5.0) 
Additional surgery,  
re-operation-rate (%) 
0/17 (0.0) 0/5 (0.0) 0/24 (0.0)/ 
Not reported 
Not reported 12/28 (42.9*) 1/8 (12.5) 
Pt with MRI-confirmed 
rupture – revision SCR 
or RTSA considered 
1/20 (5.0) 
Complications 
Procedure-related 0/17 (0.0) 0/5 (0.0) 0/24 (0.0) 0/68 (0.0) Not reported Not reported Not reported 
Device-related 0/17 (0.0) 0/5 (0.0) 0/24 (0.0) 0/68 (0.0) Not reported Not reported Not reported 
Adverse events  0/17 (0.0) 0/5 (0.0) 0/24 (0.0) Not reported Not reported 4/9 (44.4) Not reported 
Severe adverse events 0/17 (0.0) 0/5 (0.0) 0/24 (0.0)/ 
Not reported 
Not reported Not reported Not reported Not reported 
Abbreviations: AHDM = Acellular Human Dermal Matrix; ASES = American Shoulder and Elbow Surgeons; CS = Constant shoulder assessment; DASH = Disabilities of the arm, shoulder, and 
hand; OSS = Oxford Shoulder Score; RC = rotator cuff; ROM = Range Of Motion; SD = standard deviation; SPADI = Shoulder Pain and Disability Index; SSV = Subjective shoulder value; 
UCLA = University of California, Los Angeles; UK = United Kingdom; USA = United States of America; VAS = Visual analogue scale; WORC = Western Ontario Rotator Cuff Index. 
* Self-calculated. 
 
                                                             
18 10 pts. underwent follow-up MRI, resulting in confusing results. However, 30 pts underwent ultrasound showing clearer results. 
19 1 partial graft re-tear occurred because of patient noncompliance with postoperative rehabilitation. 
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Risk of bias tables and GRADE evidence profile 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement, a third researcher was involved to solve the differ-
ences. A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the 
LBI-HTA [2] and in the Guidelines of EUnetHTA [43]. The single randomised controlled trial was appraised using the Cochrane Collaboration’s Risk of Bias 
Tool [9]. The non-randomised controlled trials were appraised using The Risk Of Bias In Non-randomized Studies – of Interventions (ROBINS-I) assessment tool 
[10]. Single arm studies were appraised according to the IHE appraisal tool for case series studies [11]. 
Table A-4: Risk of bias – study level (randomised studies), see [44] 
Trial 
Adequate generation  
of randomisation sequence 
Adequate allocation 
concealment 
Blinding Selective outcome 
reporting unlikely 
No other aspects which 
increase the risk of bias 
Risk of bias – 
study level Patient Treating Physician 
Barber, 2012, [35] Yes Yes Unclear20 No21 No22 No Low 
 
Table A-5 Risk of bias of non – randomised studies comparing human dermal allograft rotator cuff tear repair versus  
RCT repair without human dermal allograft and reporting results on [ASES, CS, OSS, VAS, WORC, and SF-12], see [43] 
Trial 
Bias due to confounding Baseline confounding baseline and time-varying confounding 
Risk of bias 
judgement Confounding 
of effect 
Time-
varying 
confounding 
Time-varying 
factoras likely 
to effect 
outcome 
Appropriate 
analysis 
method 
used 
Valid and 
reliable 
measurement 
Control  
for post-
intervention 
variables 
Appropriate methis for all  
the important confounding 
domains and for time-
varying confounding 
Valid and reliable 
measurement  
of domains 
controlled for 
Gilot, 2015, [18] N N NA N NA N N N Serious risk of bias 
Pandey, 2017, [17] Y Y PY NA NA NA PN N Serious risk of bias 
Abbreviations: NA = not applicable; NI = no information; N = no; PN = probably no; PY = probably yes; Y = yes. 
 
  
                                                             
20 Patient blinding was not explicitly described. 
21 Blinding of surgeon is not possible in this intervention, but radiologist was blinded for interpretation of MRIs. 
22 Severe adverse events were not described. 
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Table A-6: Risk of bias – study level (case series), see [4] 
Study  
reference/ID 
Burkhead, 
2007 [38] 
Rotini,  
2011 [40] 
Gupta,  
2012 [20] 
Varvitsiotis, 
2015 [34] 
Leuzinger, 
2016 [39] 
Hirahara, 
2017 [19] 
Sharma, 
2018 [41] 
Study objective 
1. Was the hypothesis/aim/objective of the study clearly stated? Partial Yes Partial23 Partial24 Yes Yes Partial23 
2. Was the study conducted prospectively? No Yes Yes Yes Yes Yes No 
3. Were the cases collected in more than one centre? Unclear25 Unclear No No Unclear No No 
4. Were patients recruited consecutively? Yes Unclear Unclear Yes Unclear Unclear Unclear 
5. Were the characteristics of the patients included in the study described? Yes Yes Partial Yes Partial Yes Yes 
6. Were the eligibility criteria (i.e. inclusion and exclusion criteria)  
for entry into the study clearly stated? 
Yes Yes Yes Yes Yes Partial Partial 
7. Did patients enter the study at a similar point in the disease? Yes Yes Yes Yes Unclear26 Yes Unclear 
Intervention and co-intervention 
8. Was the intervention of interest clearly described? Yes Partial Yes Yes Yes Yes Yes 
9. Were additional interventions (co-interventions) clearly described? Partial27 Partial20 Partial20 Partial20 No No Partial20 
Outcome measures 
10 Were relevant outcome measures established a priori? No Partial28 Yes Yes Yes Yes Yes 
11 Were outcome assessors blinded to the intervention that patients received? No No No No Yes29 No No 
12. Were the relevant outcomes measured using appropriate  
objective/subjective methods? 
Partial30 Yes Yes Yes Yes Yes Yes 
13. Were the relevant outcome measures made before and after the intervention? Yes Yes Yes Yes Yes Yes Yes 
Statistical Analysis 
14. Were the statistical tests used to assess the relevant outcomes appropriate? Unclear Unclear Yes Unclear Unclear Yes Yes 
                                                             
23 Only patients and outcomes were included in the hypothesis. 
24 Only indication and intervention were described. 
25 Unclear if the senior author performed all open rotator cuff repairs of the study. 
26 Preoperative tests were reported but not described. 
27 Yes the postoperative care programme was described. 
28 Safety assessment was stated a priori, while the efficacy measures, e.g. Constant shoulder assessment was not. 
29 Yes radiographer blinded for reading MRI in postoperative assessment. 
30 Pain, function, flexion was reported with unknown scores, whereas the postoperative MRI evaluation and the ULCA state appropriate methods. 
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Study  
reference/ID 
Burkhead, 
2007 [38] 
Rotini,  
2011 [40] 
Gupta,  
2012 [20] 
Varvitsiotis, 
2015 [34] 
Leuzinger, 
2016 [39] 
Hirahara, 
2017 [19] 
Sharma, 
2018 [41] 
Results and Conclusions 
15. Was follow up long enough for important events and outcomes to occur?31 Yes Yes Yes Yes Yes Yes Yes 
16. Were losses to follow up reported? Yes Yes Yes Yes Yes Yes Yes 
17. Did the study provided estimates of random variability in the data analysis  
of relevant outcomes? 
No Partial Yes No Yes Yes Yes 
18. Were the adverse events reported? Yes Yes Yes No No Partial32 No 
19. Were the conclusions of the study supported by results? Yes Yes Unclear33 Yes Unclear27 Unclear27 Yes 
Competing interests and sources of support 
20. Were both competing interests and sources of support for the study reported? No Partial34 Partial34 Yes Partial34 Yes Yes 
Overall Risk of bias High High Moderate Low Moderate Low Low 
 
  
                                                             
31 Twelve months was considered appropriate. 
32 No severe adverse events were reported. 
33 Did not consider the limitations of the study (study design) for the conclusion. 
34 Only competing interests of the authors was reported. 
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Table A-7: Evidence profile: efficacy of human dermal allograft for massive rotator cuff tears  
Quality assessment 
Summary of findings 
Number of patients Effect  
Quality Number  
of studies  
Study  
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other  
considerations 
Surgical repair with 
human dermal allograft 
Surgical repair without 
human dermal allograft 
Absolute mean 
difference  
Pain 
Pain measured with UCLA, N=42 (follow up: mean 24 months, range 12-38) Scale 0-35 (higher better) 
1  Randomised 
controlled trial 
Not 
serious 
N/A (only  
one trial) 
Not serious Not serious None 22 20 MD 2.5* points 
higher in I1 
⨁⨁⨁◯ 
MODERATE 
Pain measured with ASES, N = 42 (follow up: mean 24 months, range 12-38) Scale 0-100 (higher better) 
1  Randomised 
controlled trial 
Not 
serious 
N/A (only  
one trial) 
Not serious Not serious None 22 20 MD 1.6* points 
higher in I2 
⨁⨁⨁◯ 
MODERATE 
Pain measured with CS, N = 42 (follow up: mean 24 months, range 12-38) Scale 0-100 (higher better) 
1  Randomised 
controlled trial 
Not 
serious 
N/A (only  
one trial) 
Not serious Not serious None 22 20 MD 11.4* points 
higher in I3 
⨁⨁⨁◯ 
MODERATE 
Pain measured with ASES, N = 35 (follow up: mean 24.9 months, range 22-26) Scale 0-100 (higher better) 
1 Non-randomised 
controlled trial 
Serious36 N/A (only  
one trial) 
Not serious Not serious None 20 15 MD 12.8* points 
higher in I2  
⨁⨁⨁◯ 
MODERATE 
Pain measured with CS, N = 26 (follow up: mean 24 months, range 2-5 years) Scale 0-100 (higher better) 
1  Non-randomised 
controlled trial 
Serious35 N/A (only  
one trial) 
Not serious Not serious None 13 13 MD 15.0* points 
higher in C3 
⨁⨁⨁◯ 
MODERATE 
Pain measured with VAS, N=35 (follow up: mean 24.9 months, range 22-26) Scale 0-10 (lower better) 
1  Non-randomised 
controlled trial 
Serious36 N/A (only  
one trial) 
Not serious Not serious None 20 15 MD 2.7* points 
lower in I  
⨁⨁⨁◯ 
MODERATE 
Pain measured with OSS, N=26 (follow up: mean 4 months, range 2-5 years) Scale 0-60 (higher better) 
1  Non-randomised 
controlled trial 
Serious35 N/A (only  
one trial) 
Not serious Not serious None 13 13 MD 9.7* points 
higher in I4  
⨁⨁⨁◯ 
MODERATE 
Range of motion 
Range of motion with UCLA, N=42 (follow up: mean 24 months, range 12-38) Max score 35 (higher better) 
1 Randomised 
controlled trial 
Not 
serious 
N/A (only  
one trial) 
Not serious Not serious None 22 20 MD 2.5* points 
higher in I1 
⨁⨁⨁◯ 
MODERATE 
                                                             
35 Risk of time-varying confounding. 
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Quality assessment 
Summary of findings 
Number of patients Effect  
Quality Number  
of studies  
Study  
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other  
considerations 
Surgical repair with 
human dermal allograft 
Surgical repair without 
human dermal allograft 
Absolute mean 
difference  
Range of motion with CS, N = 42 (follow up: mean 24 months, range 12-38) Scale 0-100 (higher better) 
1 
 
Randomised 
controlled trial 
Not 
serious 
N/A (only  
one trial) 
Not serious Not serious None 22 20 MD 11.4* points 
higher in I3  
⨁⨁⨁◯ 
MODERATE 
Range of motion with measured with ASES, N = 42 (follow up: mean 24 months, range 12-38) Scale 0-100 (higher better) 
1  Randomised 
controlled trial 
Not 
serious 
N/A (only  
one trial) 
Not serious Not serious None 22 20 MD 1.6* points 
higher in I2  
⨁⨁⨁◯ 
MODERATE 
Range of motion with CS, N = 26 (follow up: mean 24 months, range 2-5 years) Scale 0-100 (higher better) 
1 Non-randomised 
controlled trial 
Serious35 N/A (only  
one trial) 
Not serious Not serious None 13 13 MD 15.0* points 
higher in I3 
⨁⨁⨁◯ 
MODERATE 
Range of motion with measured with ASES, N = 35 (follow up: mean 24.9 months, range 22-26) Scale 0-100 (higher better) 
1 Non-randomised 
controlled trial 
Serious36 N/A (only  
one trial) 
Not serious Not serious None 20 15 MD 12.8* points 
higher in I2  
⨁⨁⨁◯ 
MODERATE 
Range of motion with WORC, N=35 (follow up: mean 24.9 months, range 22-26) Scale 0-100 (higher better) 
1 Non-randomised 
controlled trial 
Serious36 N/A (only  
one trial) 
Not serious Not serious None 20 15 MD 22.0* points 
higher in I5 
⨁⨁⨁◯ 
MODERATE 
Physical function 
Physical function with ASES, N = 42 (follow up: mean 24 months, range 12-38) Scale 0-100 (higher better) 
1  Randomised 
controlled trial 
Not 
serious 
N/A (only  
one trial) 
Not serious Not serious None 22 20 MD 1.6* points 
higher in I2  
⨁⨁⨁◯ 
MODERATE 
Physical function with CS, N = 42 (follow up: mean 24 months, range 12-38) Scale 0-100 (higher better) 
1  Not serious Not 
serious 
N/A (only  
one trial) 
Not serious Not serious None 22 20 MD 11.4* points 
higher in I3  
⨁⨁⨁◯ 
MODERATE 
Physical function with ASES, N = 35 (follow up: mean 24.9 months, range 22-26) Scale 0-100 (higher better) 
1  Non-randomised 
controlled trial 
Serious36 N/A (only  
one trial) 
Not serious Not serious None 20 15 MD 12.8* points 
higher in I2  
⨁⨁⨁◯ 
MODERATE 
Physical function with CS, N = 26 (follow up: mean 4 months, range 2-5 years) Scale 0-100 (higher better) 
1  Non-randomised 
controlled trial 
Serious35 N/A (only  
one trial) 
Not serious Not serious None 13 13 MD 15.0* points 
higher in I3  
⨁⨁⨁◯ 
MODERATE 
                                                             
36 Appropriate method controlling for confounding not used. 
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Quality assessment 
Summary of findings 
Number of patients Effect  
Quality Number  
of studies  
Study  
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other  
considerations 
Surgical repair with 
human dermal allograft 
Surgical repair without 
human dermal allograft 
Absolute mean 
difference  
Physical function with OSS, N = 26 (follow up: mean 24 months, range 2-5 years) Scale 0-60 (higher better) 
1  Non-randomised 
controlled trial 
Serious35 N/A (only  
one trial) 
Not serious Not Serious None 13 13 MD 9.7* points 
higher in I4  
⨁⨁⨁◯ 
MODERATE 
Health-related quality of life 
Health-related quality of life with WORC, N=35 (follow up: mean 24.9 months, range 22-26) Scale 0-100 (higher better) 
1  Non-randomised 
controlled trial 
Serious36 N/A (only  
one trial) 
Not serious Not serious None 20 15 MD 22.0* points 
higher in I5  
⨁⨁⨁◯ 
MODERATE 
Health-related quality of life with OSS, N = 26 (follow up: mean 24 months, range 2-5 years) Scale 0-60 (higher better) 
1  Non-randomised 
controlled trial 
Serious35 N/A (only  
one trial) 
Not serious Not serious None 13 13 MD 9.7* points 
higher in I4 
⨁⨁⨁◯ 
MODERATE 
Health-related quality of life with SF-12, N=35 (follow up: mean 24.9 months, range 22-26) Scale 0-100 (higher better) 
1 Non-randomised 
controlled trial 
Serious36 N/A (only  
one trial) 
Not serious Not serious None 20 15 Physical 
MD 5.7* points 
higher in I 
Mental 
MD 1.4* points 
higher in I  
⨁⨁⨁◯ 
MODERATE 
Abbreviations: ASES = American Shoulder and Elbow Surgeons; CI = confidence interval; CS = Constant shoulder assessment; DASH = Disabilities of the arm, shoulder, and hand;  
MD = mean difference; OSS = Oxford Shoulder Score; ROM = Range Of Motion; SF-12 = 12-item Short Form questionnaire; SPADI = Shoulder Pain and Disability Index;  
SSV = Subjective shoulder value; UCLA = University of California, Los Angeles; VAS = Visual analogue scale; WORC = Western Ontario Rotator Cuff Index. 
* Self-calculated. 
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Table A-8: Evidence profile: safety of human dermal allograft for massive rotator cuff tears  
Quality assessment 
Summary of findings 
Effect  
Quality Number  
of studies 
Study  
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other  
considerations 
Proportion  
(range) 
Safety 
Procedure-related mortality, N = 42 (follow up: mean 24 months, range 12-38, number deaths reported) 
1  Randomised 
controlled trial 
Not serious N/A  
(only one trial) 
Not serious Not serious None Overall deaths:  
0/42(0.0%) 
⨁⨁⨁⨁ 
HIGH 
Procedure-related mortality, N = 61 (follow up: range 22 months to 120 months, number deaths reported) 
2  Non-randomised 
controlled trials 
Serious35,36  Not serious Not serious Serious36,35 None Overall deaths:  
0/61 (0.0%) 
⨁⨁◯◯ 
LOW 
Procedure-related mortality, N = 174 (follow up: range 12 months to 77 months, number deaths reported) 
7 Case series Moderate20,23,34 Not serious Not serious Not serious None Overall deaths:  
0/174 (0.0%) 
⨁◯◯◯ 
VERY LOW 
Failure of repair procedure/re-tears, N = 42 (follow up: mean 24 months, range 12-38, number re-tears reported) 
1  Randomised 
controlled trial 
Not serious N/A  
(only one trial) 
Not serious Not serious None Overall failures: 
C: 9/20 (45.0%*) 
I: 3/22 (12.6%*) 
⨁⨁⨁⨁ 
HIGH 
Failure of repair procedure/re-tears, N = 61 (follow up: range 22 months to 120 months, number re-tears reported) 
2  Non-randomised 
controlled trials 
Serious35,36 Not serious Not serious Serious35,36 None Overall failures:  
10/61 (16.4%*) 
⨁⨁◯◯ 
LOW 
Failure of repair procedure/re-tears, N = 174 (follow up: range 12 months to 77 months, number re-tears reported) 
7 Case series Moderate20,23,34 Not serious Not serious Not serious None Overall failures:  
24/174 (13.8%*) 
⨁◯◯◯ 
VERY LOW 
Complications (procedure-related and device-related), N = 42 (follow up: mean 24 months, range 12-38, number complications reported) 
1  Randomised 
controlled trial 
Not serious N/A  
(only one trial) 
Not serious Not serious None Overall complications:  
0/42 (0.0%) 
⨁⨁⨁⨁ 
HIGH 
Complications (procedure-related and device-related), N = 35 (follow up: mean 24.9 months, range 22-26, number complications reported) 
1  Non-randomised 
controlled trial 
Serious36 N/A  
(only one trial) 
Not serious Serious35,36 None Overall complications:  
1/35 (2.8%*) 
⨁⨁◯◯ 
LOW 
Complications (procedure-related and device-related), N = 137 (follow up: range 12 months to 77 months, number complications reported) 
4 Case series Moderate20,34 Not serious Not serious Not serious None Overall complications:  
0/137 (0.0%) 
⨁◯◯◯ 
VERY LOW 
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Quality assessment 
Summary of findings 
Effect  
Quality Number  
of studies 
Study  
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other  
considerations 
Proportion  
(range) 
Adverse events, N = 42 (follow up: mean 24 months, range 12-77 months, number adverse events reported) 
1  Randomised 
controlled trial 
Not serious N/A  
(only one trial) 
Not serious Not serious None Overall adverse events:  
18/42 (42.8%*): 
C: 14/20 (70.0%*) 
I: 4/22 (18.0%*) 
⨁⨁⨁⨁ 
HIGH 
Adverse events, N = 55 (follow up: range 12 months to 40 months, number adverse events reported) 
4 Case series Moderate20,34 Not serious Not serious Not serious None Overall adverse events:  
4/55 (7.3%*) 
⨁◯◯◯ 
VERY LOW 
Abbreviation: CI = confidence interval.  
* Self-calculated. 
Nomenclature for GRADE tables:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty  
Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1) 
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Applicability table 
Table A-9: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The patient population (n=277) did not appear to differ significantly between studies. Surgeons 
consider this procedure only in patients who are young (<65 years), with a massive rotator cuff 
tear where healing is unlikely. The included studies were conducted primarily in the United 
States/Canada, followed by the United Kingdom and locations in Europe.  
Though they are all from developed Western countries, it cannot be known for sure if the practice 
represents that in Austria. Patient demographics may be reflective of practice in terms of gender 
where mostly males have been treated, and post-operative treatments. 
Intervention The intervention, rotator cuff surgery using human dermal allograft, is well defined in the literature. 
Techniques may vary between surgeons, but the use of the dermal allograft to augment the repair 
appears consistent across studies. 
Comparators Due to our stringent inclusion criteria, all comparative studies included had the same comparator  
of rotator cuff surgery without using human dermal allograft. 
The randomised controlled trial stated rotator cuff tears without human dermal allograft was the 
comparator. The surgical technique is not described, it is assumed to be the currently agreed best 
technique, which is superior capsular reconstraction (SCR). Pandey et al. reported patients received 
the same procedure, partial repair, with or without the addition of human dermal allograft. Gilot  
et al. reported the surgical technique for both groups differed only in the use of the allograft. 
It is expected this is representative of clinical practice. 
Outcomes The three studies used for efficacy all reported pain, range of motion, and physical function using  
a range of scores. These studies had mean follow up of 2 years, ranging from one to five years.  
As the biggest impact of rotator cuff tear is pain and limited movement, these outcomes over the 
time period reported seem appropriate. 
Setting The efficacy studies were carried out in the United States, the United Kingdom, and Canada.  
The safety studies were in the United States, the United Kingdom, Greece, Itali and Switzerland. 
Settings were hospitals and universitis affiliated with hospitals. 
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List of ongoing randomised controlled trials 
There were four randomised controlled trials and one non-randomised controlled trial on human dermal 
allograft for massive rotator cuff tears identified in trial databases. 
Table A-10: List of ongoing randomised controlled trials of human dermal allograft for massive rotator cuff tears 
Identifier/ 
Trial name 
Patient 
population 
Intervention Comparison 
Primary 
Outcome, FU 
Primary 
completion 
date 
Sponsor 
NCT03551509 
LifeNet: 
Extracellular Matrix 
Graft in Rotator 
Cuff Repair 
Large (3-5 cm) or 
massive (>5 cm) 
rotator cuff tear 
proven on MRI 
(N=70) 
RC repair 
augmented 
with 
ArthroFLEX 
ECM scaffold 
graft 
RC repair 
using 
standard 
practice, no 
ECM graft 
Tendon healing, 
FU=12 months 
June 2020 
* Recruiting 
The 
Cleveland 
Clinic, USA 
NCT03617562 
Superior Capsule 
Reconstruction vs 
Partial Repair of 
Massive Rotator 
Cuff Tears 
Massive (>4 cm) 
rotator cuff tear 
proven on MRI 
(N=44) 
RC repair 
augmented 
with dermal 
allograft 
Partial RC 
repair using 
standard 
practice 
ASES, 
FU=NR 
May 2020 
* Recruiting 
Sunnybrook 
Health 
Sciences 
Centre, 
Canada 
NCT01987973 
Allograft 
Reconstruction of 
Massive Rotator 
Cuff Tears vs Partial 
Repair Alone 
Large or massive 
(>3 cm) rotator 
cuff tear proven 
on MRI 
(N=30) 
Partial RC 
repair with 
Allopatch HD 
patch 
allograft 
Partial RC 
repair 
WORC 
FU=NR 
February 2017 
* Status 
unknown 
Ivan Wong, 
Nova Scotia 
Health 
Authority, 
Canada 
NCT03425500 
Massive Rotator 
Cuff Tear 
Reconstruction 
Large or massive 
(>3 cm) rotator 
cuff tear proven 
on MRI 
(N=60) 
RC repair 
augmented 
with the 
GraftJacket 
RC repair Maintenance  
of the 
Acromiohumeral 
distance shown 
on xray 
June 2019 
* Not yet 
recruiting 
Ivan Wong, 
Nova Scotia 
Health 
Authority, 
Canada 
Abbreviations: ASES = The American Shoulder and Elbow Surgeons Shoulder Score; ECM = extracellular matrix;  
FU = follow-up; NR = not reported; MRI = magnetic resonance imaging; RC = rotator cuff; RC = rotator cuff;  
WORC = Western Ontario Rotator Cuff Index. 
 
Table A-11: List of ongoing non-randomised controlled trials of human dermal allograft for massive rotator cuff tears 
Identifier/ 
Trial name 
Patient 
population Intervention Comparison 
Primary 
Outcome, 
FU 
Primary 
completion 
date Sponsor 
NCT03739749 
Arthroscopic 
Superior Capsular 
Reconstruction 
(SCR) – Study of 
Different Types 
of Grafts 
Rotator cuff tear 
arthropathy, 
Hamada stage  
1 or 2 proven  
on MRI 
(N=40) 
6 arms for 
SCR with 
grafts, of 
which one 
used fascia 
lata allograft 
Fascia lata 
autograft, achilles 
tendon allograft, 
bovine pericardium 
xenograft, swine 
dermal xenograft, 
or collagen graft 
Constant 
Score 
assessment 
FU=NR 
October 2020 
* Recruiting 
Hospital de 
Egas Moniz, 
Portugal 
Abbreviations: FU = follow-up; NR = not reported; MRI = magnetic resonance imaging; SCR = superior capsular repair. 
 
  
Appendix 
LBI-HTA | 2019 79 
Literature search strategies 
Search strategy for The Cochrane Library 
Search Date: 14/12/2018 
ID Search 
#1 MeSH descriptor: [Rotator Cuff Injuries] explode all trees 
#2 (("rotator cuff*" or supraspinat* or infraspinat* or supra-spinat* or infra-spinat*) NEAR (tear* or rupture*  
or injur* or damage* or defect*)) (Word variations have been searched) 
#3 (supraspinat*) (Word variations have been searched) 
#4 ("supraspinatus tendon") (Word variations have been searched) 
#5 (infraspinatus) (Word variations have been searched) 
#6 ((massive NEAR (tear* or rupture* or injur* or damage* or defect*) NEAR ("rotator cuff*" or supraspinat*  
or infraspinat* or supra-spinat* or infra-spinat* ))) (Word variations have been searched) 
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6 (Word variations have been searched) 
#8 (capsul* NEAR (reconstruct* or augment* or repa*)) (Word variations have been searched) 
#9 ((superior NEAR (capsul* NEAR (reconstruct* or augment* or repa*)))) (Word variations have been searched) 
#10 (SCR):ti,ab,kw (Word variations have been searched) 
#11 MeSH descriptor: [Fascia Lata] explode all trees 
#12 ("fascia lata") (Word variations have been searched) 
#13 #11 OR #12 (Word variations have been searched) 
#14 MeSH descriptor: [Autografts] explode all trees 
#15 (autograft*) (Word variations have been searched) 
#16 #14 OR #15 (Word variations have been searched) 
#17 #13 AND #16 (Word variations have been searched) 
#18 ("fascia lata" NEAR autograft*) (Word variations have been searched) 
#19 MeSH descriptor: [Allografts] explode all trees 
#20 (allograft*) (Word variations have been searched) 
#21 MeSH descriptor: [Acellular Dermis] explode all trees 
#22 ("regenerative tissue matrix") (Word variations have been searched) 
#23 (GraftJacket*) (Word variations have been searched) 
#24 (Graft Jacket*) (Word variations have been searched) 
#25 (Arthro Flex) (Word variations have been searched) 
#26 (ArthroFLEX*) (Word variations have been searched) 
#27 #8 OR #9 OR #10 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR  
#26 (Word variations have been searched) 
#28 #7 AND #27 (Word variations have been searched) 
Total: 15 Hits 
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Search strategy for CRD (DARE, NHS-EED, HTA) 
No. Search terms Results 
1 (capsul* NEAR (reconstruct* OR augment* OR repa*)) 5 
 
 
Search strategy for Embase 
No. Query Results Results Date 
#30 #8 AND #29 359 13 Dec 2018 
#29 #9 OR #10 OR #11 OR #12 OR #13 OR #20 OR #21 OR #22 OR #23 OR #24 OR 
#25 OR #26 OR #27 OR #28 
19,507 13 Dec 2018 
#28 arthroflex*:ti,ab,de 13 13 Dec 2018 
#27 graftjacket*:ti,ab,de 64 13 Dec 2018 
#26 'graftjacket'/exp 12 13 Dec 2018 
#25 'regenerat* tissue* matri*':ti,ab,de 33 13 Dec 2018 
#24 'acellular dermal matrix'/exp 1,660 13 Dec 2018 
#23 'skin allograft'/exp 2,141 13 Dec 2018 
#22 'derm* allograft*':ti,ab,de 210 13 Dec 2018 
#21 ('fascia lata' NEAR/5 autograft*):ti,ab,de 107 13 Dec 2018 
#20 #16 AND #19 208 13 Dec 2018 
#19 #17 OR #18 24,665 13 Dec 2018 
#18 'autograft*':ti,ab,de 24,665 13 Dec 2018 
#17 'autograft'/exp  13,129 13 Dec 2018 
#16 #14 OR #15 3,403 13 Dec 2018 
#15 ‘fascia lata':ti,ab,de 3,403 13 Dec 2018 
#14 'fascia lata'/exp 1,838 13 Dec 2018 
#13 'fascia lata graft'/exp 39 13 Dec 2018 
#12 (superior NEAR/5 (reconstruct* OR augment* OR repa*)):ti,ab,de 3,252 13 Dec 2018 
#11 (capsul* NEAR/5 (reconstruct* OR augment* OR repa*)):ti,ab,de 1,882 13 Dec 2018 
#10 scr:ti,ab 10,446 13 Dec 2018 
#9 'superior capsular reconstruction'/exp 17 13 Dec 2018 
#8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 12,661 13 Dec 2018 
#7 (massive NEAR/5 ('rotator cuff*' OR supraspinat* OR infraspinat*)):ti,ab,de 854 13 Dec 2018 
#6 (('rotator cuff*' OR supraspinat* OR 'supraspinat*' OR infraspinat* OR 'infra 
spinat*') NEAR/5 (tear* OR rupture* OR injur* OR damage* OR defect*)):ti,ab,de 
10,905 13 Dec 2018 
#5 'infraspinatus tendon'/exp 52 13 Dec 2018 
#4 'supraspinatus tendon rupture'/exp 11 13 Dec 2018 
#3 'supraspinatus tear'/exp 22 13 Dec 2018 
#2 'supraspinatus tendon tear'/exp 26 13 Dec 2018 
#1 'rotator cuff injury'/exp 10,048 13 Dec 2018 
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Search strategy for Medline 
Database: Ovid MEDLINE(R) <1946 to December Week 1 2018>, Ovid MEDLINE(R) Epub Ahead of Print  
<December 12, 2018>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <December 12, 2018>,  
Ovid MEDLINE(R) Daily Update <December 12, 2018> 
Search Strategy: 
1 exp Rotator Cuff Injuries/ 
2 ((rotator cuff* or supra?spinat* or infra?spinat*) adj5 (tear* or rupture* or injur* or damage* or defect*)).mp. 
3 exp Rotator Cuff 
4 supra?spinat*.mp. 
5 infra?spinat*.mp. 
6 3 or 4 or 5 
7 injuries.fs. 
8 6 and 7 
9 (massive adj5 ((tear* or rupture* or injur* or damage* or defect*) adj5 (rotator cuff* or supra?spinat* or 
infra?spinat*))).mp. 
10 1 or 2 or 8 or 9 
11 (capsul* adj5 (augment* or reconstruct* or repa*)).mp. 
12 (superior adj5 (capsul* adj5 (augment* or reconstruct* or repa*))).mp. 
13 SCR.ti,ab. 
14 exp Fascia Lata/ 
15 fascia lata.mp. 
16 14 or 15 
17 exp Autografts/ 
18 autograft*.mp. 
19 17 or 18 
20 16 and 19 
21 (fascia lata adj5 autograft*).mp. 
22 exp ALLOGRAFTS/ 
23 allograft*.mp. 
24 exp Acellular Dermis 
25 regenerat* tissue* matri*.mp 
26 GraftJacket*.mp. 
27 Graft Jacket*.mp 
28 ArthroFLEX*.mp 
29 11 or 12 or 13 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 
30 10 and 29 
Search date: 14/12/2018 
Hits: 220 
 
 
 
  
 
